Note: Descriptions are shown in the official language in which they were submitted.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 1 -
BIOMARKER OF DISEASE
FIELD OF THE INVENTION
[0001] The present invention relates generally to methods for the diagnosis
and treatment
of melanoma.
BACKGROUND OF THE INVENTION
[0002] Melanoma is an aggressive form of skin cancer that is responsible for
more than
80% of all skin cancer related deaths (Lewis et al., 2005, American Cancer
Society,
104(4): 1678-1686). Furthermore, the incidence of cutaneous melanoma, the most
aggressive and treatment resistant type of skin cancer, continues to increase
worldwide
(Siegel et al., 2014, CA: A Cancer Journal for Clinicians, 64(1): 9-29). It is
widely
recognised that the early detection of melanoma can significant reduce both
morbidity and
mortality. Detection of Stage 0 in situ melanoma may result in five-year
survival rate as
high as 99%. However, this rate plummets to an average of 63% for Stage III
disease and
an average of 17% for Stage IV disease. Therefore, early detection is central
to improving
the therapeutic outcomes for patients diagnosed with this aggressive disease.
[0003] Currently, the most common method for the diagnosis of melanoma are
visual
screening methods, such as dermoscopy, reflectance confocal microscopy, total
body
photography, telederatology and mobile phone applications. Unfortunately,
these methods
are limited by high subjectivity, observer bias and the ability to identify a
visible lesion.
Moreover, it is questionable whether these methods are suitable for screening
people at
higher risk of melanoma, for example, patients with a substantial number of
moles (i.e.,
>100), those with a family history, cases of occult melanoma or those with
very thin and
unpigmented primary lesions (Loescher et al., 2013, Seminars in Oncology
Nursing, 29(3):
170-181).
[0004] The limitations of visual screening methods are exacerbated by the
inefficiencies
associated with screening large populations for melanoma, largely due to the
time required
to screen each individual patient. Furthermore, although Australians are
advised to
maintain routine annual skin checks, there is little to no capacity for this
practice due to a
limited number of dermatologists available, especially in rural or remote
regions (Chen et
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 2 -
al., 2006, Journal of General Internal Medicine, 21: 678-682).
[0005] The total health care cost for the diagnosis, treatment and management
of
melanoma is estimated to amount to $30 million annually in Australia
(Australian Institute
of Health and Welfare, 2010, Cancer in Australia: an overview). Previous data
has shown
that only 5% of these costs are spent on the management of early stage
disease, which
includes the costs of primary tumour diagnosis and excision, while the
remaining 95% is
spent on the treatment and management of advanced disease (Durbec et al.,
2010, Archives
of Dermatology, 139(5): 607-612). Therefore, early detection and treatment not
only
improves patient outcomes, but also significantly reduces the financial burden
of disease
on the Australian health care system. Complementary diagnostic tools, such as
a blood test,
are needed to increase melanoma screening efficiency and lower the emphasis on
invasive
and expensive biopsies (Goldsmith, 2013, Journal of the American Academy of
Dermatology, 68(3): 517-519). Blood samples are routinely collected as an
adjunct to
currently utilised diagnostic approaches, therefore, a number of blood-based
biomarkers
have been proposed for melanoma prognosis, indication of recurrence and
assessment of
treatment response, including microRNAs (miRNAs) (Stark et al., 2015,
EBioMedicine,
2(7): 671-680), circulating tumour cells (CTCs) (Freeman et al., 2012, Journal
of
Translational Medicine, 10: 192) and circulating tumour DNA (ctDNA) (Grey et
al., 2015,
Oncogene, 6(39): 42008-42018 and Tsao et al., 2015, Scientific Reports,
5(11198): 1-11).
However, none of these proposed biomarkers appear to be sufficiently sensitive
to detect
the initial transformation to malignancy and may not be reliable diagnostic
biomarkers for
early stage disease.
[0006] Autoantibodies that bind to tumour-associated autoantigens can be
detected in
patient serum months to years prior to the clinical manifestation of a primary
tumour (Qiu
et al., 2008, Journal of Clinical Oncology, 26: 5060-5066; Anderson and
LaBaer, 2005,
Journal of Proteome Research, 4: 1123-1133). This is possibly due to a change
in their
expression, structural confirmation, and presence of mutations or their
release into the
surrounding blood serum due to cancer cell lysis (Zaenker et al., 2016,
Autoimmunity
Reviews, 15: 477-483). As a result, autoantibodies have been proposed to be
valuable
biomarkers for the early detection of many types of cancers, such as prostate,
lung, colon,
liver and breast cancer (Zaenker and Ziman, 2013, Cancer Epidemiology,
Biomarkers &
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 3 -
Prevention, 22(12): 2161-2181). Autoantibodies have also been suggested to be
suitable
prognostic markers for melanoma (Sabel et al., 2011, International Journal of
Proteomics,
1-9; Zornig et al., 2015, International Journal of Cancer, 136: 138-151).
However, these
studies have not investigated autoantibodies as a marker of early stage
disease, nor have
they identified a clinically relevant subset of autoantibody biomarkers that
can be used to
diagnose melanoma with sufficient sensitivity, specificity and predictive
value.
Accordingly, there remains an urgent need for the identification of
autoantibody
biomarkers to improve the diagnosis, prognosis and treatment of melanoma.
SUMMARY OF THE INVENTION
[0007] In one aspect, the present invention provides a method of determining
whether a
subject has melanoma, the method comprising:
a) measuring the expression of one or more autoantibodies selected from the
group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 in a
biological sample obtained from a subject; and
b) comparing the level of expression of the one or more autoantibodies in the
biological sample to a reference value, wherein the reference value is
representative
of a known or predetermined level of expression of the one or more
autoantibodies
in a reference sample or a plurality of reference samples from a subject or
subjects
that have never been diagnosed with cancer, melanoma or an autoimmune disease;
wherein a level of expression of the one or more autoantibodies in the
biological sample
greater than the reference value provides an indication that the subject has
melanoma, and
wherein the melanoma is Stage 0, Stage I or Stage II melanoma.
[0008] In an embodiment, the step of measuring the expression of one or more
autoantibodies in the biological sample comprises measuring the expression of
anti-
ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1.
[0009] The inventor's findings enable a therapeutic regimen, which can be
adopted or
prescribed, with a view to preventing or delaying the progression of melanoma
in a
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 4 -
subject. Thus, in another aspect, the present invention provides a method of
treating a
subject with melanoma, the method comprising the steps of:
a) measuring the expression of one or more autoantibodies selected from the
group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 in a
biological sample obtained from a subject; and
b) comparing the level of expression of the one or more autoantibodies in the
biological sample to a reference value, wherein the reference value is
representative
of a known or predetermined level of expression of the one or more
autoantibodies
in a reference sample or plurality of reference samples from a subject or
subjects
that have never been diagnosed with cancer, melanoma or an autoimmune disease,
wherein a level of expression of the one or more autoantibodies in the
biological
sample greater than the reference value provides an indication that the
subject has
melanoma;
c) identifying a subject that has melanoma from step (b); and
d) exposing the subject identified in step (c) as having melanoma to a
therapeutic
regimen for preventing or delaying the progression of melanoma,
wherein the melanoma is Stage 0, Stage I or Stage II melanoma.
[0010] In an embodiment, the step of measuring the expression of one or more
autoantibodies in the biological sample comprises measuring the expression of
anti-
ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1.
[0011] In another aspect of the present invention, there is provided a kit
comprising one or
more reagents and/or devices for use in performing the method of the present
invention, as
disclosed herein.
BRIEF DESCRIPTION OF THE FIGURES
[0012] Embodiments of the disclosure are described herein, by way of non-
limiting
example only, with reference to the following drawings.
[0013] Figure 1 is a schematic representation of the study design for the
identification of
diagnostic autoantibodies in melanoma.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
-5-
100141 Figure 2 is a graphical representation of serum scores (y-axis) in
melanoma
patients and healthy controls (x-axis) for the top 139 individual melanoma-
associated
biomarkers in (A) cohort 1 and (B) cohort 2. Horizontal lines represent the
median and
interquartile range (IQR) of all serum scores with dots representing
individual samples.
Statistical significance was determined by Mann-Whitney U test.
[0015] Figure 3 is a schematic representation of the protein interaction
network for the top
139 individual melanoma-associated biomarkers. The thickness of the line
indicates the
level of confidence. Proteins without any identified interactions were not
included in this
schematic.
[0016] Figure 4 is a graphical representation of (A) inclusion frequency (%; x-
axis) and
(B) weighted mean rank (x-axis) for the 20 most frequently included
autoantibody
biomarkers in the 1000 random forest analysis.
[0017] Figure 5 is a graphical representation of serum scores (y-axis) in
melanoma
patients and healthy controls (x-axis) for the 27 melanoma-associated
biomarkers with the
highest weighted mean rank score in (A) cohort 1 and (B) cohort 2.
[0018] Figure 6 is a schematic representation of the regression analysis of
the best
combination of the identified autoantibody biomarkers. Melanoma patients are
represented
by red boxes and healthy controls are blue boxes.
[0019] Figure 7 is a graphical representation of cumulative specificity (blue
line),
sensitivity (red line) with overall classification rate (%; y-axis) of the 10
autoantibody
biomarkers (x-axis).
[0020] Figure 8 is a graphical representation of ROC and AUC for individual
biomarkers
as well as their combination in the discovery cohort.
DETAILED DESCRIPTION OF THE INVENTION
[0021] Throughout this specification and the claims which follow, unless the
context
requires otherwise, the word "comprise", and variations such as "comprises"
and
"comprising", will be understood to imply the inclusion of a stated integer or
step or group
of integers or steps but not the exclusion of any other integer or step or
group of integers or
steps.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
-6-
100221 The articles "a" and "an" are used herein to refer to one or to more
than one (i.e., to
at least one) of the grammatical object of the article. By way of example, "an
agent" means
one agent or more than one agent.
[0023] In the context of this specification, the term "about" is understood to
refer to a
range of numbers that a person of skill in the art would consider equivalent
to the recited
value in the context of achieving the same function or result.
Methods of diagnosis
[0024] The present invention is predicated, at least in part, on the
inventors' surprising
finding that the expression of one or more autoantibodies selected from the
group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-
UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 can detect melanoma
with sufficient sensitivity and specificity to be clinically relevant.
[0025] In one aspect of the present invention, there is provided a method of
determining
whether a subject has melanoma, the method comprising:
a) measuring the expression of one or more autoantibodies selected from the
group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 in a
biological sample obtained from a subject; and
b) comparing the level of expression of the one of more autoantibodies in the
biological sample to a reference value, wherein the reference value is
representative
of a known or predetermined level of expression of the one or more
autoantibodies
in a reference sample or a plurality of reference samples from a subject or
subjects
that have never been diagnosed with cancer, melanoma or an autoimmune disease;
wherein a level of expression of the one or more autoantibodies in the
biological sample
greater than the reference value provides an indication that the subject has
melanoma,
wherein the melanoma is Stage 0, Stage I or Stage II melanoma.
Autoantibodies
[0026] "Autoantibodies" or "AAbs" are antibodies produced by the immune system
that
are directed against one or more of an individual's own proteins. Since
tumours originate
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 7 -
from autologous cells containing self-antigens, the abnormal exposure or
presentation of
these "tumour-associated antigens" or "TAAs" facilitates an autoimmune
response.
[0027] Autoantibodies have become of particular interest as cancer biomarkers
as they can
be easily extracted from serum via minimally invasive blood collection.
Moreover, they
exhibit increased levels in very early stages and persist for extended periods
after the
corresponding antigen is no longer detectable. Importantly, the production of
autoantibodies may precede clinical conformation of a tumour by several months
or years
(Caron et al., 2007, Molecular Cell Proteomics, 6(7): 1115-1122).
[0028] Increased levels of autoantibodies have been detected in the serum of
patients with
very early stage cancer (Zayakin et al., 2013, International Journal of
Cancer, 132: 137-
147) and in patients with breast (Anderson et al., 2011, Journal of Proteome
Research, 10:
85-96), lung (Chapman et al., 2011, Clinical Cancer Research, 17(6): 1474-
1480),
gastrointestinal (Zayakin et al., supra), ovarian (Anderson et al., supra) and
prostate
(Wang et al., 2005, New England Journal of Medicine, 353(12): 1224-1235)
cancer.
Therefore, although autoantibodies are recognised to be sensitive biomarkers
for the
detection and surveillance on many types of primary tumours, their diagnostic
utility in
melanoma is yet to be conclusively demonstrated.
[0029] As disclosed herein, the present inventors have shown that the
expression of one or
more autoantibodies selected from the group consisting of anti-ZBTB7B, anti-
PRKCH,
anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2,
anti-
MSN and anti-TPM1 have diagnostic capacity with respect to melanoma,
including, in an
embodiment, the diagnosis of early stage melanoma (i.e., Stage 0, I or II
melanoma).
[0030] The present inventors have also shown that the combined expression of
the anti-
ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1 autoantibodies significantly improves
the
diagnostic capacity for identifying whether or not a subject has melanoma. For
instance,
the inventors have found that the diagnostic capacity of the expression of
anti-ZBTB7B,
anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-
MAPK8 tv2, anti-MSN and anti-TPM1 autoantibodies has a sensitivity of 79% and
specificity of 84%, with an AUC of 0.828 for identifying a subject with
melanoma as
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 8 -
shown in Figures 7 and 8 herein.
[0031] It is to be understood that the expression of any combination or
permutation of the
one or more autoantibodies selected from the group consisting of anti-ZBTB7B,
anti-
PRKCH, anti-TP53, anti-PC TK1, anti-PQB Pl, anti-UBE2V1, anti-IRF4, anti-
MAPK8 tv2, anti-MSN and anti-TPM1 can be used in accordance with the present
invention. In an embodiment, the one or more autoantibodies are anti-ZBTB7B,
anti-
PRKCH, anti-TP53, anti-PC TK1, anti-PQB Pl, anti-UBE2V1, anti-IRF4, anti-
MAPK8 tv2, anti-MSN and anti-TPM1.
[0032] The phrase "one or more autoantibodies" is to be understood as meaning
at least
one autoantibody selected from the group consisting of anti-ZBTB7B, anti-
PRKCH, anti-
TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN
and anti-TPM1, at least two autoantibodies selected from the group consisting
of anti-
ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1, at least three autoantibodies selected
from
the group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-
PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1, at least four
autoantibodies selected from the group consisting of anti-ZBTB7B, anti-PRKCH,
anti-
TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN
and anti-TPM1, at least five autoantibodies selected from the group consisting
of anti-
ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1, at least six autoantibodies selected
from the
group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-
PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1, at least seven
autoantibodies selected from the group consisting of anti-ZBTB7B, anti-PRKCH,
anti-
TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN
and anti-TPM1, at least eight autoantibodies selected from the group
consisting of
ZBTB7B, PRKCH, TP53, PCTK1, PQBP1, UBE2V1, IRF4, MAPK8 tv2, MSN and
TPM1, at least nine autoantibodies selected from the group consisting of anti-
ZBTB7B,
anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-
MAPK8 tv2, anti-MSN and anti-TPM1, or at least ten autoantibodies selected
from the
group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-
PQBP1,
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 9 -
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1.
[0033] It is to be understood that, where a combination of two or more
autoantibodies is
selected and employed in accordance with the present invention, it is
desirable that the
autoantibodies are selected for combination with the one or more
autoantibodies in a
combination that will improve, or at least not negate or reduce, the
diagnostic capacity of
the one or more other autoantibodies. Methods of assessing whether or not one
or more
autoantibodies improve, or at least do not negate or reduce the capacity of
the one or more
autoantibodies in a combination to diagnose melanoma, as herein described,
would be
familiar to persons skilled in the art having regard to the present
disclosure.
[0034] In an embodiment, the method comprises measuring the expression of anti-
ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1 autoantibodies in a biological sample
obtained from a subject.
[0035] The term "autoantibody" includes vertebrate autoantibodies selected
from the
group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-
PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1, or homologs
thereof. Suitable vertebrates that fall within the scope of the invention
include, but are not
restricted to, any member of the subphylum Chordata including primates,
rodents (e.g.,
mice rats, guinea pigs), lagomorphs (e.g., rabbits, hares), bovines (e.g.,
cattle), ovines (e.g.,
sheep), caprines (e.g., goats), porcines (e.g., pigs), equines (e.g., horses),
canines (e.g.,
dogs), felines (e.g., cats), avians (e.g., chickens, turkeys, ducks, geese,
companion birds
such as canaries, budgerigars etc.), marine mammals (e.g., dolphins, whales),
reptiles
(snakes, frogs, lizards, etc.), and fish. In an embodiment, the autoantibodies
are human
autoantibodies selected from the group consisting of anti-ZBTB7B, anti-PRKCH,
anti-
TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN
and anti-TPM1.
[0036] As used herein, the term "autoantibody" also includes homologs thereof.
The term
"homolog" typically refers to a peptide with similar biological activity,
although differs in
amino acid sequence at one or more amino acid positions when the sequences are
aligned.
For example, the amino acid sequences of two homologous autoantibodies may
differ by
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 10 -
only one amino acid residue within the aligned amino acid sequences.
Alternatively, two
homologous autoantibodies may differ by two or more amino acid residues when
aligned.
Homologous autoantibodies may also differ by up to approximately 5%, 10%, 20%
or 25%
of the amino acid residues when the amino acid sequences of the two homologs
are
aligned.
[0037] Homologs of autoantibodies may be found in the same species (i.e.,
between two or
more individuals of the same species), in related species and/or sub-species,
or in different
species. For example, for a human autoantibody, homologs include those found
in non-
human vertebrates and non-vertebrates. Suitable vertebrates that fall within
the scope of
the invention include, but are not restricted to, any member of the subphylum
Chordata
including primates, rodents (e.g., mice rats, guinea pigs), lagomorphs (e.g.,
rabbits, hares),
bovines (e.g., cattle), ovines (e.g., sheep), caprines (e.g., goats), porcines
(e.g., pigs),
equines (e.g., horses), canines (e.g., dogs), felines (e.g., cats), avians
(e.g., chickens,
turkeys, ducks, geese, companion birds such as canaries, budgerigars etc),
marine
mammals (e.g., dolphins, whales), reptiles (snakes, frogs, lizards, etc.), and
fish. A
preferred homolog is one found in a primate (e.g., a human, ape, monkey,
chimpanzee).
Alternatively, a laminin chain subunit homolog may be from the same species
(e.g.,
human).
[0038] Generally, homologs will have at least about 70%, 71%, 72%, 73%, 74%,
75%,
76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a
particular amino acid or nucleotide sequence, as determined, for example, by
sequence
alignment programs known in the art using default parameters (see, e.g.,
Needleman &
Wunsch, 1970). In specific embodiments, the percent identity between
nucleotide
sequences is determined using the GAP program in the GCG software package
(available
at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40,
50, 60,
70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. An non-limiting set of
parameters (and
the one that should be used unless otherwise specified) includes a Blossum 62
scoring
matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift
gap penalty of
5. In some embodiments, the percent identity or similarity between amino acid
or
nucleotide sequences can be determined using the algorithm of Meyers & Miller
(1989)
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 11 -
which has been incorporated into the ALIGN program (version 2.0), using a
PAM120
weight residue table, a gap length penalty of 12 and a gap penalty of 4.
Measuring the expression of autoantibodies
[0039] The term "expression" is used herein in its broadest context to denote
a measurable
presence of the autoantibodies of the present invention, including the
production of RNA
message (gene expression) or translation of RNA message into proteins or
polypeptides
(protein expression). For example, the term "autoantibody expression" includes
(i) the
production of autoantibody RNA message (i.e., autoantibody gene expression),
(ii) the
translation of autoantibody RNA message into autoantibody protein and/or (iii)
the
transport of autoantibody protein to the cell surface and into circulation.
[0040] In an embodiment, the step of measuring the expression of one or more
autoantibodies in the biological sample comprises measuring the protein
expression of the
one or more autoantibodies in the biological sample.
[0041] Suitable methods for measuring autoantibody expression would be known
to
persons skilled in the art. In some embodiments, it may be desirable to
measure the
expression of autoantibodies at the protein level. It will be understood that,
in some
instances, it may be more desirable to measure a gene expression product, such
as a
transcript (e.g., mRNA) levels, as described elsewhere herein.
[0042] Methods of measuring expression products such as proteins and
transcripts are
known to persons skilled in the art, with illustrative examples described
herein. In some
embodiments, measuring the expression of autoantibodies comprises determining
the level
of mRNA encoding the autoantibodies.
[0043] As used herein the terms "level" and "amount" are used interchangeably
herein to
refer to a quantitative amount (e.g., moles or number), a semi-quantitative
amount, a
relative amount (e.g., weight % or mole % within a class or a ratio), a
concentration, and
the like. Thus, these terms encompass absolute or relative amounts or
concentrations of
autoantibodies in a sample, including levels in a population of subjects
represented as
mean levels and standard deviations, as shown in some of the Figures herein.
[0044] Autoantibodies may be quantified or detected using any suitable
technique,
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 12 -
including, but not limited to, nucleic acid- and protein-based assays. In
illustrative nucleic
acid-based assays, nucleic acid is isolated from cells contained in a
biological sample
according to standard methodologies (Sambrook, et al., 1989, Molecular
Cloning: A
Laboratory Manual; and Ausubel et al., 1994, Current Protocols in Molecular
Biology).
The nucleic acid is typically fractionated (e.g., poly A+ RNA) or whole cell
RNA. Where
RNA is used as the subject of detection, it may be desired to convert the RNA
to a
complementary DNA. In some embodiments, the nucleic acid is amplified by a
template-
dependent nucleic acid amplification technique. A number of template dependent
processes are available to amplify the autoantibody-encoding nucleotide
sequences present
in a given sample. An exemplary nucleic acid amplification technique is the
polymerase
chain reaction (referred to as PCR), which is described in detail in U.S. Pat.
Nos.
4,683,195, 4,683,202 and 4,800,159, Ausubel et al. (supra), and in Innis et
al., (1990).
Briefly, in PCR, two primer sequences are prepared that are complementary to
regions on
opposite complementary strands of the autoantibody nucleotide sequence. An
excess of
deoxynucleotide triphosphates are added to a reaction mixture along with a DNA
polymerase, e.g., Taq polymerase. If a cognate autoantibody nucleotide
sequence is present
in a sample, the primers will bind to the sequence and the polymerase will
cause the
primers to be extended along the sequence by adding on nucleotides. By raising
and
lowering the temperature of the reaction mixture, the extended primers will
dissociate from
the autoantibody nucleotide sequence to form reaction products, excess primers
will bind
to the autoantibody nucleotide sequence and to the reaction products and the
process is
repeated. A reverse transcriptase PCR amplification procedure may be performed
in order
to quantify the amount of mRNA amplified. Methods of reverse transcribing RNA
into
cDNA are well known and described in Sambrook et al., 1989, supra. Alternative
methods
for reverse transcription utilize thermostable, RNA-dependent DNA polymerases.
These
methods are described in WO 90/07641. Polymerase chain reaction methodologies
are well
known in the art.
[0045] In an embodiment, the template-dependent amplification involves
quantification of
transcripts in real-time. For example, RNA or DNA may be quantified using the
Real-Time
PCR technique (Higuchi et al., 1992, Biotechnology, 11(9): 1026-1030). By
determining
the concentration of the amplified products of the target DNA in PCR reactions
that have
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 13 -
completed the same number of cycles and are in their linear ranges, it is
possible to
determine the relative concentrations of the specific target sequence in the
original DNA
mixture. If the DNA mixtures are cDNAs synthesized from RNAs isolated from
different
tissues or cells, the relative abundance of the specific mRNA from which the
target
sequence was derived can be determined for the respective tissues or cells.
This direct
proportionality between the concentration of the PCR products and the relative
mRNA
abundance is only true in the linear range of the PCR reaction. The final
concentration of
the target DNA in the plateau portion of the curve is determined by the
availability of
reagents in the reaction mix and is independent of the original concentration
of target
DNA. In specific embodiments, multiplexed, tandem PCR (MT-PCR) is employed,
which
uses a two-step process for gene expression profiling from small quantities of
RNA or
DNA, as described for example in US Pat. Appl. Pub. No. 20070190540. In the
first step,
RNA is converted into cDNA and amplified using multiplexed gene specific
primers. In
the second step each individual gene is quantitated by real time PCR.
[0046] In some embodiments, autoantibody nucleic acids are quantified using
blotting
techniques, which are well known to those of skill in the art. Southern
blotting involves the
use of DNA as a target, whereas Northern blotting involves the use of RNA as a
target.
Each provides different types of information, although cDNA blotting is
analogous, in
many aspects, to blotting or RNA species. Briefly, a probe is used to target a
DNA or RNA
species that has been immobilized on a suitable matrix, often a filter of
nitrocellulose. The
different species should be spatially separated to facilitate analysis. This
often is
accomplished by gel electrophoresis of nucleic acid species followed by
"blotting" on to
the filter. Subsequently, the blotted target is incubated with a probe
(usually labelled)
under conditions that promote denaturation and re-hybridisation. Because the
probe is
designed to base pair with the target, the probe will bind a portion of the
target sequence
under renaturing conditions. Unbound probe is then removed, and detection is
accomplished as described above. Following detection/quantification, one may
compare
the results seen in a given subject with a control reaction or a statistically
significant
reference group or population of control subjects as defined herein. In this
way, it is
possible to correlate the amount of a biomarker nucleic acid detected with the
likelihood
that a subject has melanoma.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 14 -
[0047] Also contemplated herein are biochip-based technologies such as those
described
by Hacia et al. (1996) and Shoemaker et al. (1996). Briefly, these techniques
involve
quantitative methods for analysing large numbers of genes rapidly and
accurately. By
tagging genes with oligonucleotides or using fixed probe arrays, one can
employ biochip
technology to segregate target molecules as high-density arrays and screen
these molecules
on the basis of hybridization. See also Pease et al. (1994); Fodor et al.
(1991). Briefly,
nucleic acid probes to autoantibody nucleotide sequences are made and attached
to
biochips to be used in screening and diagnostic methods, as outlined herein.
The nucleic
acid probes attached to the biochip are designed to be substantially
complementary to
specific expressed autoantibody nucleotide sequences, i.e., the target
sequence (either the
target sequence of the sample or to other probe sequences, for example in
sandwich
assays), such that hybridization of the target sequence and the probes of the
present
invention occur. This complementarity need not be perfect; there may be any
number of
base pair mismatches, which will interfere with hybridization between the
target sequence
and the nucleic acid probes of the present invention. However, if the number
of
mismatches is so great that no hybridization can occur under even the least
stringent of
hybridization conditions, the sequence is not a complementary target sequence.
In certain
embodiments, more than one probe per sequence is used, with either overlapping
probes or
probes to different sections of the target being used. That is, two, three,
four or more
probes, with three being desirable, are used to build in a redundancy for a
particular target.
The probes can be overlapping (i.e. have some sequence in common), or
separate.
[0048] In an illustrative biochip analysis, oligonucleotide probes on the
biochip are
exposed to or contacted with a nucleic acid sample suspected of containing one
or more
biomarker polynucleotides under conditions favouring specific hybridization.
Sample
extracts of DNA or RNA, either single or double-stranded, may be prepared from
fluid
suspensions of biological materials, or by grinding biological materials, or
following a cell
lysis step which includes, but is not limited to, lysis effected by treatment
with SDS (or
other detergents), osmotic shock, guanidinium isothiocyanate and lysozyme.
Suitable
DNA, which may be used in the method of the invention, includes cDNA. Such DNA
may
be prepared by any one of a number of commonly used protocols as for example
described
in Ausubel, et al., supra, and Sambrook, et al., supra.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 15 -
[0049] Suitable RNA, which may be used in the method of the invention,
includes
messenger RNA, complementary RNA transcribed from DNA (cRNA) or genomic or
subgenomic RNA. Such RNA may be prepared using standard protocols as for
example
described in the relevant sections of Ausubel, et al., supra and Sambrook, et
al., supra).
[0050] cDNA may be fragmented, for example, by sonication or by treatment with
restriction endonucleases. Suitably, cDNA is fragmented such that resultant
DNA
fragments are of a length greater than the length of the immobilized
oligonucleotide
probe(s) but small enough to allow rapid access thereto under suitable
hybridization
conditions. Alternatively, fragments of cDNA may be selected and amplified
using a
suitable nucleotide amplification technique, as described for example above,
involving
appropriate random or specific primers.
[0051] Usually the target biomarker polynucleotides are detectably labelled so
that their
hybridization to individual probes can be determined. The target
polynucleotides are
typically detectably labelled with a reporter molecule illustrative examples
of which
include chromogens, catalysts, enzymes, fluorochromes, chemiluminescent
molecules,
bioluminescent molecules, lanthanide ions (e.g., Eu34), a radioisotope and a
direct visual
label. In the case of a direct visual label, use may be made of a colloidal
metallic or non-
metallic particle, a dye particle, an enzyme or a substrate, an organic
polymer, a latex
particle, a liposome, or other vesicle containing a signal producing substance
and the like.
Illustrative labels of this type include large colloids, for example, metal
colloids such as
those from gold, selenium, silver, tin and titanium oxide. In some
embodiments, in which
an enzyme is used as a direct visual label, biotinylated bases are
incorporated into a target
polynucleotide.
[0052] The hybrid-forming step can be performed under suitable conditions for
hybridizing oligonucleotide probes to test nucleic acid including DNA or RNA.
In this
regard, reference may be made, for example, to "Nucleic Acid Hybridization, A
Practical
Approach (Homes & Higgins, 1985). In general, whether hybridization takes
place is
influenced by the length of the oligonucleotide probe and the polynucleotide
sequence
under test, the pH, the temperature, the concentration of mono- and divalent
cations, the
proportion of G and C nucleotides in the hybrid-forming region, the viscosity
of the
medium and the possible presence of denaturants. Such variables also influence
the time
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 16 -
required for hybridization. The preferred conditions will therefore depend
upon the
particular application. Such empirical conditions, however, can be routinely
determined
without undue experimentation.
[0053] After the hybrid-forming step, the probes are washed to remove any
unbound
nucleic acid with a hybridization buffer. This washing step leaves only bound
target
polynucleotides. The probes are then examined to identify which probes have
hybridized to
a target polynucleotide. The hybridization reactions are then detected to
determine which
of the probes has hybridized to a corresponding target sequence. Depending on
the nature
of the reporter molecule associated with a target polynucleotide, a signal may
be
instrumentally detected by irradiating a fluorescent label with light and
detecting
fluorescence in a fluorimeter; by providing for an enzyme system to produce a
dye which
could be detected using a spectrophotometer; or detection of a dye particle or
a coloured
colloidal metallic or non metallic particle using a reflectometer; in the case
of using a
radioactive label or chemiluminescent molecule employing a radiation counter
or
autoradiography. Accordingly, a detection means may be adapted to detect or
scan light
associated with the label which light may include fluorescent, luminescent,
focused beam
or laser light. In such a case, a charge couple device (CCD) or a photocell
can be used to
scan for emission of light from a probe: target polynucleotide hybrid from
each location in
the micro-array and record the data directly in a digital computer. In some
cases, electronic
detection of the signal may not be necessary. For example, with enzymatically
generated
colour spots associated with nucleic acid array format, visual examination of
the array will
allow interpretation of the pattern on the array. In the case of a nucleic
acid array, the
detection means is suitably interfaced with pattern recognition software to
convert the
pattern of signals from the array into a plain language genetic profile. In
certain
embodiments, oligonucleotide probes specific for different biomarker
polynucleotides are
in the form of a nucleic acid array and detection of a signal generated from a
reporter
molecule on the array is performed using a 'chip reader'. A detection system
that can be
used by a 'chip reader' is described for example by Pirrung et al (U.S. Patent
No.
5,143,854). The chip reader will typically also incorporate some signal
processing to
determine whether the signal at a particular array position or feature is a
true positive or
maybe a spurious signal. Exemplary chip readers are described for example by
Fodor et al
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 17 -
(U.S. Patent No., 5,925,525). Alternatively, when the array is made using a
mixture of
individually addressable kinds of labelled microbeads, the reaction may be
detected using
flow cytometry.
[0054] In other illustrative embodiments, autoantibody protein levels can be
measured
using protein-based assays known in the art. For example, an antibody-based
technique
may be employed to determine the level of an autoantibody in a sample, non-
limiting
examples of which include immunoassays, such as the enzyme-linked
immunosorbent
assay (ELISA), immunohistochemistry (IHC) and the radioimmunoassay (RIA).
[0055] In an embodiment, protein expression is measured using a multiplexed
protein
expression analysis method. In another embodiment, the multiplexed protein
expression
analysis method is a protein microarray or Luminex bead array.
[0056] Protein-capture arrays that permit simultaneous detection and/or
quantification of a
large number of proteins may also be employed. For example, low-density
protein arrays
on filter membranes, such as the universal protein array system (Ge, 2000)
allow imaging
of arrayed antigens using standard ELISA techniques and a scanning charge-
coupled
device (CCD) detector. Immuno-sensor arrays have also been developed that
enable the
simultaneous detection of clinical analytes. It is now possible using protein
arrays, to
profile protein expression in bodily fluids, such as in serum of healthy or
diseased subjects.
Exemplary protein capture arrays include protein function arrays comprising
spatially
addressed protein-binding molecules (i.e., antigens), which can facilitate
extensive parallel
analysis of autoantibodies with specificity for the antigens that comprise the
protein
function array. Central to this type of analysis is the retention of the
correctly folded
protein confirmation of the arrayed antigen. Protein function arrays have been
shown to
have the required properties of specificity and acceptable background, and are
available
commercially (e.g., Sengenics). Various methods for the preparation of protein
function
arrays have been reported (see, e.g., Gnjatic et al., 2009, Journal of
Immunological
Methods, 341(50): 1-2; PCT/GB01/00395, PCT/GB02/05499, PCT/GB03/00362).
Individual spatially distinct functional proteins are typically attached to a
support surface,
which is generally planar or contoured. Common physical supports include glass
slides,
silicon, microwells, nitrocellulose or PVDF membranes, and magnetic and other
microbeads.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 18 -
[0057] Particles in suspension can also be used as the basis of arrays,
providing they are
coded for identification; systems include colour coding for microbeads (e.g.,
available
from Luminex, Bio-Rad and Nanomics Bios ystems) and semiconductor nanocrystals
(e.g.,
QDotsTM, available from Quantum Dots), and barcoding for beads (UltraPlexTM,
available
from Smartbeads) and multimetal microrods (NanobarcodesTM particles, available
from
Surromed). Beads can also be assembled into planar arrays on semiconductor
chips (e.g.,
available from LEAPS technology and BioArray Solutions). Where particles are
used,
individual protein-capture agents (e.g., anti-autoantibody antibodies or
autoantibody-
binding fragments thereof) are typically attached to an individual particle to
provide the
spatial definition or separation of the array. The particles may then be
assayed separately,
but in parallel, in a compartmentalized way, for example in the wells of a
microtiter plate
or in separate test tubes.
[0058] In an illustrative example, a patient or control serum sample is
delivered to a
protein function array under conditions suitable for protein or peptide
binding, and the
array is washed to remove unbound or non-specifically bound components of the
sample
from the array. Next, the array is incubated with fluorescently-labelled
antibody to detect
the interaction between array antigens and serum autoantibodies. The presence
or amount
of protein or peptide bound to each feature of the array is detected using a
suitable
fluorescence detection system. The amount of protein bound to a feature of the
array is
proportional to the intensity of fluorescence. In certain embodiments, local
background
fluorescence obtained from control features of the array are automatically
subtracted and
relative fluorescent units (rfu) for each feature of the array is recorded.
[0059] In some embodiments, the protein function array is Immunome Protein
Array
(Sengenics).
[0060] Another illustrative example of a protein-capture array is a Luminex-
based
multiplex assay, which is a bead-based multiplexing assay, where beads are
internally dyed
with fluorescent dyes to produce a specific spectral address. Biomolecules
(such as an
oligo or antibody) can be conjugated to the surface of beads to capture
analytes of interest;
that is, autoantibodies or a nucleic acid molecule encoding same. Flow
cytometric or other
suitable imaging technologies known to persons skilled in the art can then be
used for
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 19 -
characterization of the beads, as well as for detection of analyte presence.
The Luminex
technology enables are large number of proteins, genes or other gene
expression products
(e.g., 100 or more, 200 or more, 300 or more, 400 or more) to be detected
using very small
sample volume (e.g., in a 96 or 384-well plate).
[0061] In some embodiments, the expression of the autoantibodies can be
normalised
against a housekeeping biomarker. The term "housekeeping biomarker" refers to
a
biomarker or group of biomarkers (e.g., polynucleotides and/or polypeptides),
which are
typically found at a constant level in the cell type(s) or tissue(s) being
analysed and across
the conditions being assessed. In some embodiments, the housekeeping biomarker
is a
"housekeeping gene." A "housekeeping gene" refers herein to a gene or group of
genes
which encode proteins whose activities are essential for the maintenance of
cell function
and which are typically found at a constant level in the cell type(s) being
analysed and
across the conditions being assessed.
[0062] In other embodiments, the expression of the autoantibodies measured
using a
protein array can be normalised by both intra- and inter-array data
normalisation. For
example, the overall median value of all median relative fluorescent units
(rfu) of each
protein in a protein function array (excluding data from control proteins) is
calculated and
intra-array normalisation achieved by dividing the median of the quadruplicate
spots of
each protein on the array, by the overall median value of all the proteins on
the array in
each sample. Inter-array normalisation can be achieved using bioinformatics
software
packages that are known in the art. For example, inter-array normalisation can
be achieved
using the normalize.quantiles package in R (Bolstad et al., 2003,
Bioinformatics, 19(2):
185-193).
[0063] It would be understood by those skilled in the art, as described
elsewhere herein,
that the method of analysing the expression of autoantibodies in a biological
sample can be
quantitative, semi-quantitative or qualitative in nature. For example,
quantitative analyses
will typically provide a concentration or number of an autoantibody nucleic
acid molecule
or protein in the sample within an appropriate error margin (e.g., mean +/-
standard
deviation). By contrast, semi-quantitative or qualitative analyses will
typically provide an
indication of the relative amount of an autoantibody in a sample. This may
involve a
comparison of an amount of an autoantibody protein in a first sample with an
amount of an
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 20 -
autoantibody protein in a second sample and making a determination as to the
relative
amount of the autoantibody protein between the first and second samples.
[0064] It will be understood by persons skilled in the art that, where a
comparison is made
to a reference value, then the manner in which the biological sample is
assessed for the
expression of the one or more autoantibodies should be substantially identical
to the
manner in which the reference value is derived in order to ensure that an
appropriate
comparison can be made for the purposes of determining whether or not a
subject has
melanoma.
[0065] In an embodiment, the methods disclosed herein comprise measuring the
protein
expression of the one or more autoantibodies selected from the group
consisting of anti-
ZB TB7B , anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQB Pl, anti-UBE2V1, anti-
IRF4,
anti-MAPK8 tv2, anti-MSN and anti-TPM1 in the biological sample by
quantitative or
semi-quantitative protein analysis methods, either as individual biomarkers or
as a
multiplexed biomarker panel. These methods will be known to persons skilled in
the art,
an illustrative example of which is disclosed elsewhere herein.
[0066] In an embodiment, the step of measuring the expression of the one or
more
autoantibodies selected from the group consisting of anti-ZBTB7B, anti-PRKCH,
anti-
TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN
and anti-TPM1 in the biological sample comprises measuring the protein
expression of the
one or more autoantibodies in the biological sample.
[0067] In another embodiment, the step of measuring the expression of the one
or more
autoantibodies comprises measuring the protein expression of each of anti-
ZBTB7B, anti-
PRKCH, anti-TP53, anti-PC TK1, anti-PQB Pl, anti-UBE2V1, anti-IRF4, anti-
MAPK8 tv2, anti-MSN and anti-TPM1 in the biological sample.
Melanoma
[0068] Melanoma is a malignant tumour of melanocytes, which are the cells that
produce
the pigment melanin and are derived from the neural crest. Although the
majority of
melanomas arise in the skin, they may also arise from mucosal surfaces or at
other sites to
which neural cells migrate, including the uveal tract. Malignant melanoma
accounts for the
largest number of deaths attributed to skin cancer and is predicted to be the
eighth most
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 21 -
common cause of cancer death in Australia in 2017 (Australian Institute of
Health and
Welfare, 2017, Cancer in Australia).
[0069] The term "melanoma" includes melanoma, metastatic melanoma, melanomas
derived from melanocytes or nevus cells, superficial spreading melanoma,
nodular
melanoma, lentigo maligna melanoma, acral lentiginous melanoma, demoplastic
melanoma, ocular melanoma (i.e., uveal and conjunctival), polyploid melanoma,
naevoid
melanoma and anorectal melanoma).
[0070] Melanoma is commonly diagnosed by visual screening methods, such as
dermoscopy, reflectance confocal microscopy, total body photography,
telederatology and
mobile phone applications. Thereafter, histological conformation of the
diagnosis is
performed by taking an excision biopsy and, in some cases, a sentinel lymph
node biopsy.
If melanoma is found in a tissue sample, an assessment will usually be
undertaken to
determine the stage, or extent, of the disease, with respect to the size and
spread of the
melanoma. The TNM system is often employed for this purpose, where (T) denotes
the
size of the melanoma, (N) denotes the spread of the melanoma to the lymph
nodes and (M)
denotes the spread of melanoma cells to different parts of the body.
[0071] Once the TNM is determined, a stage of 0, I, II, III or IV is assigned
to the
melanoma. Stage 0 is the earliest stage of melanoma and limited to in situ
tumours that are
confined to the cells in the epidermis with no detectable cancer cells in the
dermis. Stage I
melanoma can be defined in two ways: 2mm in thickness without ulceration or
detectable
cancer cells in the regional lymph nodes or metastases at distant sites; or up
to 1 mm in
thickness with ulceration but no detectable cancer cells in the regional lymph
nodes or
metastases at distant sites. Stage II tumours are classified into three
distinct sub-stages,
stage IIA have a primary tumour that ranges from 1 mm but not more than 4 mm
in
thickness with ulceration but no detectable cancer cells in the regional lymph
nodes or
metastases at distant sites; stage JIB have a primary tumour that ranges from
2.01 mm to
>4 mm in thickness with ulceration but no detectable cancer cells in the
regional lymph
nodes or metastases at distant sites; and stage IIC have a primary tumour >4
mm in
thickness with ulceration but no detectable cancer cells in the regional lymph
nodes or
metastases at distant sites. Stage III tumours are classified into three
distinct sub-stages,
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 22 -
with primary tumours of any thickness and cancer cells present to a various
extent in
regional lymph nodes but no metastases at distinct sites. Finally, Stage IV
tumours
represent the most advanced stage of disease and are characterised by a
primary tumour of
any thickness with metastases present in regional lymph nodes and distant
sites.
[0072] In an embodiment, the present invention is particularly adapted for the
diagnosis of
a Stage 0, I or II melanoma.
[0073] Until the present invention, there has been no reliable diagnostic test
available that
can identify whether a patient has melanoma using blood- or serum-based
biomarkers. This
is particularly the case for early stage melanomas, where detection may result
in
significantly improved patient prognosis.
[0074] The inventors have surprisingly shown that the expression of one or
more
autoantibodies selected from the group consisting of anti-ZBTB7B, anti-PRKCH,
anti-
TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN
and anti-TPM1 can be used to diagnose melanoma, and in particular, early stage
melanoma.
Subject
[0075] The terms "subject," "individual" and "patient" are used
interchangeably herein to
refer to any subject to which the present disclosure may be applicable,
particularly a
vertebrate subject, and even more particularly a mammalian subject. Suitable
vertebrate
animals that fall within the scope of the invention include, but are not
restricted to, any
member of the subphylum Chordata including primates, rodents (e.g., mice rats,
guinea
pigs), lagomorphs (e.g., rabbits, hares), bovines (e.g., cattle), ovines
(e.g., sheep), caprines
(e.g., goats), porcines (e.g., pigs), equines (e.g., horses), canines (e.g.,
dogs), felines (e.g.,
cats), avians (e.g., chickens, turkeys, ducks, geese, companion birds such as
canaries,
budgerigars etc), marine mammals (e.g., dolphins, whales), reptiles (snakes,
frogs, lizards,
etc.), and fish. In some embodiments, the subject is a primate (e.g., a human,
ape, monkey,
chimpanzee). In a preferred embodiment, the subject is a human.
Biological sample
[0076] The biological sample can be any sample in which changes in the
expression of
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
-23 -
autoantibodies reflect the risk of melanoma. Suitable biological samples could
be
determined by persons skilled in the art. For example, the level of expression
of the one or
more autoantibodies selected from the group consisting of anti-ZBTB7B, anti-
PRKCH,
anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2,
anti-
MSN and anti-TPM1 in a biological sample obtained from a first subject who
undergoing
screening to detect melanoma can be compared to a level of expression of the
one or more
autoantibodies in a biological sample obtained from substantially the same
anatomical
region of a second subject who is free of melanoma and/or has had no history
of
melanoma, wherein a higher level of expression of the one or more antibodies
in the
biological sample from the first subject as compared to the level of
expression in the
biological sample from the second subject is indicative that the first subject
has melanoma,
in accordance with the method of the present invention.
[0077] A biological sample may include a sample that has been obtained,
extracted,
untreated, treated, diluted or concentrated from a subject. In some
embodiments, the
biological sample has not been extracted from the subject, particularly where
the
determination steps in accordance with the present invention (e.g., the
expression of the
panel of autoantibodies) can be performed in situ.
[0078] Non-limiting examples of suitable biological samples include, but are
not limited
to, tissue, such as a biopsy sample or a resected tumour, bodily fluid (for
example, blood,
serum, plasma, saliva, urine, tears, peritoneal fluid, ascetic fluid, vaginal
secretion, breast
fluid, breast milk, lymph fluid, cerebrospinal fluid or mucosa secretion),
umbilical cord
blood, chorionic villi, amniotic fluid, an embryo, embryonic tissues, lymph
fluid,
cerebrospinal fluid, mucosa secretion, or other body exudate, fecal matter and
one or more
cells or extracts thereof that express laminin chain subunits (nucleic acid or
protein),
including subcellular structures obtained using protocols well established
within the art.
[0079] In an embodiment, the biological sample comprises blood or a component
of blood,
such as peripheral blood, or a fraction or extract thereof. The biological
sample may
comprise blood cells, such as mature, immature or developing leukocytes,
including
lymphocytes, polymorphonuclear leukocytes, neutrophils, monocytes,
reticulocytes,
basophils, coelomocytes, eosinophils, megakaryocytes, macrophages, dendritic
cells,
natural killer cells, or fraction of such cells (e.g., a nucleic acid or
protein fraction).
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 24 -
[0080] In an embodiment disclosed herein, the component of blood is serum. In
another
embodiment, the component of blood is plasma.
[0081] The biological sample may be processed and analysed for the purpose of
determining the expression of the one or more autoantibodies, in accordance
with the
present invention, almost immediately following collection (i.e., as a fresh
sample), or it
may be stored for subsequent analysis. If storage of the biological sample is
desired or
required, it would be understood by persons skilled in the art that it should
ideally be
stored under conditions that preserve the integrity of the biomarker of
interest within the
sample (e.g., at -80 C).
[0082] The terms "obtain", "obtaining", "obtained" and the like, as used
herein, are meant
to come into possession. Biological or reference samples so obtained include,
for example,
nucleic acid extracts or polypeptide extracts isolated or derived from a
particular source.
For instance, the extract may be isolated directly from a biological tissue of
the subject.
Reference Value
[0083] The methods disclosed herein comprise a comparison step (i.e., to
identify whether
the subject has melanoma) in which the expression of the one or more
autoantibodies
selected from the group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-
PCTK1,
anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 in
the
biological sample of the test subject is compared to the expression of the one
or more
autoantibodies in a reference sample or a plurality of reference samples that
is measured
prior to, concurrently or subsequent to the expression of the one or
autoantibodies in the
biological sample from the test subject, wherein the reference sample or
plurality of
reference samples is obtained from a different subject or subjects who have
never been
diagnosed with cancer, melanoma or an autoimmune disease. It is to be
understood,
however, that the comparison step (i.e., to identify whether the subject has
melanoma) does
not need to rely upon a comparison with a level of expression of the one or
more
autoantibodies in the biological sample to the level of expression in
reference sample. For
example, the comparison may be carried out using a reference value; that is, a
known or
predetermined level of expression of the one or more autoantibodies that is
associated with
the absence of melanoma, as described elsewhere herein.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 25 -
[0084] The term "reference value" is referred to interchangeably herein as a
"control
value". In an illustrative example, the comparison may be carried out using a
reference
value that is representative of a known or predetermined level of expression
of the one or
more autoantibodies in a reference sample or a plurality of reference samples,
which is
associated with the absence of melanoma, as described elsewhere herein. The
term
"reference sample" is also referred to herein as a "control sample".
[0085] The reference value is typically a predetermined level of expression of
the one or
more autoantibodies that is representative of the level of expression in a
particular cohort
or population of subjects (e.g., normal healthy subjects, subjects that have
never been
diagnosed with melanoma, any other type of cancer or any autoimmune diseases,
etc.). The
reference value may be represented as an absolute number, or as a mean value
(e.g., mean
+/- standard deviation), such as when the reference value is derived from
(i.e.,
representative of) a population of individuals.
[0086] The reference value may be equal to or not significantly different from
the level of
expression of the one or more autoantibodies in a sample population
representative of
patients who have never been diagnosed with cancer, melanoma or an autoimmune
disease. Thus, a level of expression of the one or more autoantibodies in a
biological
sample from a test subject that is greater than the reference value is
indicative of melanoma
in the test subject. Conversely, a level of expression of the one or more
autoantibodies in a
biological sample from a test subject that is equal to or less than the
reference value
indicates that the test subject does not have melanoma.
[0087] Whilst persons skilled in the art would understand that using a
reference value that
is derived from a plurality of reference samples is likely to provide a more
accurate
representation of the level of expression in that particular population (e.g.,
for the purposes
of the methods and protocols disclosed herein), in some embodiments, the
reference value
can be a level of expression of the one or more autoantibodies in a single
reference sample.
[0088] In an embodiment, the reference value is representative of a level of
expression of
the one or more autoantibodies in a reference sample or a plurality of
reference samples of
a healthy subject or subjects, wherein the term "healthy subject" is defined
as a subject that
has never been diagnosed with cancer, melanoma or an autoimmune disease,
wherein a
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 26 -
level of expression of the one or more autoantibodies in the biological sample
greater than
the reference value is indicative that the subject has melanoma.
[0089] In an embodiment, the reference value is representative of a level of
expression of
the one or more autoantibodies in a reference sample or a plurality of
reference samples of
a healthy subject or subjects that have never been diagnosed with cancer,
melanoma or an
autoimmune disease, wherein a level of expression of the one or more
autoantibodies in the
biological sample less than or equal to the reference value is indicative that
the subject
does not have melanoma.
[0090] In an embodiment, the reference value is representative of a level of
expression of
the one or more autoantibodies in a biological sample of a subject or subjects
that have
never been diagnosed with cancer, melanoma or an autoimmune disease, wherein
the level
of expression of the one or more autoantibodies in the biological sample is
greater than the
reference value and is indicative of early stage melanoma, wherein "early
stage melanoma"
means Stage 0, I or II melanoma.
[0091] For any particular autoantibody, a distribution of autoantibody
expression levels for
subjects who have or do not have melanoma may overlap. Under such conditions,
a test
may not absolutely distinguish a subject who has melanoma from a subject who
does not
have melanoma with absolute (i.e., 100%) accuracy, and the area of overlap
indicates
where the test cannot distinguish the two subjects. Accordingly, in an
embodiment the
reference value can be selected, above which (or below which, depending on how
the
expression of one or more autoantibodies changes during melanoma progression)
the test is
considered to be "positive" and below which the test is considered to be
"negative." The
area under the receiver operating characteristic (ROC) curve (AUC) provides
the C-
statistic, which is a measure of the probability that the perceived
measurement will allow
correct identification of a condition (see, e.g., Hanley et al., 1982,
Radiology, 143(1): 29-
36).
[0092] In some embodiments, AUC or ROC values are used as a measure of a
method's
ability to detect melanoma. The term "area under the curve" or "AUC" refers to
the area
under the curve of a ROC curve, both of which are well known in the art. AUC
measures
are useful for comparing the accuracy of a classifier across the complete data
range.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 27 -
Classifiers with a greater AUC have a greater capacity to classify unknowns
correctly
between two groups of interest (e.g., a healthy subject group and a melanoma
group). ROC
curves are useful for plotting the performance of a particular feature (e.g.,
any of the one or
more autoantibodies selected from the group consisting of anti-ZBTB7B, anti-
PRKCH,
anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2,
anti-
MSN and anti-TPM1 and/or any item of additional biomedical information) in
distinguishing or discriminating between two populations (e.g., cases having
melanoma
and control healthy subjects). Typically, the feature data across the entire
population (e.g.,
the cases and controls) are sorted in ascending order based on the value of a
single feature.
Then, for each value for that feature, the true positive and false positive
rates for the data
are calculated. The sensitivity is determined by counting the number of cases
above the
value for that feature and then dividing by the total number of cases. The
specificity is
determined by counting the number of controls below the value for that feature
and then
dividing by the total number of controls. Although this definition refers to
scenarios in
which a feature is elevated in cases compared to controls, this definition
also applies to
scenarios in which a feature is lower in cases compared to the controls (in
such a scenario,
samples below the value for that feature would be counted). ROC curves can be
generated
for a single feature as well as for other single outputs, for example, a
combination of two
or more features can be mathematically combined (e.g., added, subtracted,
multiplied, etc.)
to produce a single value, and this single value can be plotted in a ROC
curve.
Additionally, any combination of multiple features, in which the combination
derives a
single output value, can be plotted in a ROC curve. These combinations of
features may
comprise a test. The ROC curve is the plot of the sensitivity of a test
against the specificity
of the test, where sensitivity is traditionally presented on the vertical axis
and specificity is
traditionally presented on the horizontal axis. Thus, "AUC ROC values" are
equal to the
probability that a classifier will rank a randomly chosen positive instance
higher than a
randomly chosen negative one. An AUC ROC value may be thought of as equivalent
to the
Mann-Whitney U test, which tests for the median difference between scores
obtained in
the two groups considered if the groups are of continuous data, or to the
Wilcoxon test of
ranks.
[0093] In an embodiment, the reference value is determined by reference to the
AUC ROC
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 28 -
values relating to the expression of the one or more autoantibodies selected
from the group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-
UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1.
[0094] In some embodiments, the expression of the one or more autoantibodies
selected
from the group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1,
anti-
PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 is
selected
to discriminate between subjects with or without melanoma with at least about
50%, 55%
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% accuracy or having a C-statistic of at
least
about 0.50, 0.55, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95.
[0095] In the case of a positive likelihood ratio, a value of 1 indicates that
a positive result
is equally likely among subjects in both the "melanoma" and "healthy subject"
groups; a
value greater than 1 indicates that a positive result is more likely in the
melanoma group;
and a value less than 1 indicates that a positive result is more likely in the
healthy subject
group. In this context, "melanoma group" is meant to refer to a population of
reference
individuals considered to melanoma and a "healthy subject" is meant to refer
to a group of
subjects that have never been diagnosed with cancer, melanoma or an autoimmune
disease.
In the case of a negative likelihood ratio, a value of 1 indicates that a
negative result is
equally likely among subjects in both the "melanoma" and "healthy subject"
groups; a
value greater than 1 indicates that a negative result is more likely in the
"melanoma"
group; and a value less than 1 indicates that a negative result is more likely
in the "healthy
subject" group. In the case of an odds ratio, a value of 1 indicates that a
positive result is
equally likely among subjects in both the "melanoma" and "healthy subject"
groups; a
value greater than 1 indicates that a positive result is more likely in the
"melanoma" group;
and a value less than 1 indicates that a positive result is more likely in the
"healthy subject"
group. In the case of an AUC ROC value, this is computed by numerical
integration of the
ROC curve. The range of this value can be 0.5 to 1Ø A value of 0.5 indicates
that a
classifier (e.g., an autoantibody expression profile) is no better than a 50%
chance to
classify unknowns correctly between two groups of interest, while 1.0
indicates the
relatively best diagnostic accuracy. In certain embodiments, autoantibodies
and/or
autoantibody panels are selected to exhibit a positive or negative likelihood
ratio of at least
about 1.5 or more or about 0.67 or less, at least about 2 or more or about 0.5
or less, at
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 29 -
least about 5 or more or about 0.2 or less, at least about 10 or more or about
0.1 or less, or
at least about 20 or more or about 0.05 or less.
[0096] In certain embodiments, the one or more autoantibodies selected from
the group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-
UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 are selected to
exhibit
an AUC ROC value of greater than 0.5, preferably at least 0.6, more preferably
0.7, still
more preferably at least 0.8, even more preferably at least 0.9, and most
preferably at least
0.95.
Therapeutic regimen
[0097] A subject who is identified as having melanoma can be stratified into a
treatment
group where an appropriate therapeutic regimen can be adopted or prescribed
with a view
to treating or preventing melanoma and/or melanoma progression. Conversely,
subjects
identified as having early stage melanoma can be spared an otherwise taxing
therapeutic
regimen or, alternatively, a less aggressive therapeutic regimen (e.g., a
lower dose of
chemotherapeutic agent or radiation dose) can be adopted or prescribed. Thus,
in an
embodiment, the methods disclosed herein further comprise the step of exposing
(i.e.,
subjecting) the subject identified as having melanoma to a therapeutic regimen
for treating
the melanoma and/or melanoma progression, including a therapeutic regimen for
preventing or delaying melanoma progression.
[0098] In an embodiment, the therapeutic regimen comprises surgery and the
administration of a chemotherapeutic agent, radiotherapy, immunotherapy and/or
targeted
molecular therapy.
[0099] In another aspect disclosed herein, there is provided a method of
treating a subject
with melanoma, the method comprising the steps of:
a) measuring the expression of one or more autoantibodies selected from the
group
consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1,
anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 in a
biological sample obtained from a subject;
b) comparing the level of expression of the one or more autoantibodies in the
biological sample to a reference value, wherein the reference value is
representative
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 30 -
of a level of expression of the one or more autoantibodies in a reference
sample or
a plurality of reference samples from a subject or subjects that have never
been
diagnosed with cancer, melanoma or an autoimmune disease, wherein a level of
expression of the one or more autoantibodies in the biological sample greater
than
the reference value provides an indication that the subject has melanoma;
c) identifying a subject that has melanoma from step (b); and
d) exposing the subject identified in step (c) as having melanoma to a
therapeutic
regimen for preventing or delaying the progression of the melanoma,
wherein the melanoma is Stage 0, Stage I or Stage II melanoma.
[0100] Suitable therapeutic regimens will be familiar to persons skilled in
the art, the
choice of which is likely to be determined by factors such as, but not limited
to, the type of
melanoma (e.g., superficial spreading melanoma, nodular melanoma, lentigo
maligna
melanoma, acral lentiginous melanoma, demoplastic melanoma, ocular melanoma
(i.e.,
uveal and conjunctival), polyploid melanoma, naevoid melanoma and anorectal
melanoma), the severity of the melanoma (e.g., stage of progression), the age
and general
health status of the patient, etc. In an embodiment, the method the
therapeutic regimen
comprises surgery, optionally followed by the administration of a
chemotherapeutic agent,
radiotherapy, immunotherapy and/or targeted molecular therapy. Where melanoma
is
detected by blood test, the therapeutic regimen will further comprise the
identification of
the primary lesion by a skin check prior to surgical removal of the primary
lesion,
optionally followed by the administration of a chemotherapeutic agent,
radiotherapy,
immunotherapy and/or target therapy.
[0101] Suitable chemotherapeutic agents will be known to persons skilled in
the art.
Illustrative examples of suitable chemotherapeutic agents include dacarbazine,
temozolomide, nab-paclitaxel, paclitaxel, cisplatin, carboplatin and
vinblastine.
[0102] Radiation therapy (also referred to as radiotherapy) uses high-energy
electromagnetic radiation to damage cancer cells and stop them from
proliferating. When
used, it is generally in combination with surgery and chemotherapy, or used
only with
chemotherapy in cases where the individual is unable to undergo resection.
Radiation
therapy may also be used to relieve pain or blockage by shrinking the tumour
during
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
-31 -
palliative care.
[0103] Suitable immunotherapies will be known to persons skilled in the art.
Illustrative
examples of suitable immunotherapies include immune checkpoint inhibitors
(e.g., PD-1
inhibitors such as pembrolizumab and nivolumab), CTLA-4 inhibitors (e.g.,
ipilimumab),
cytokines (e.g., interferon- and interleukin-2), oncolytic virus therapy
(e.g., talimogene
laherparepvec or "T-VEC"), Bacille Calmette-Guerin (BCG) vaccine, imiquimod
cream,
monoclonal antibodies (e.g., alemtuzumab and trastuzumab) conjugated
monoclonal
antibodies (e.g., ibritumomab tiuxetan, brentuximab vedotin and ado-
trastuzumab
emtansine), bispecific monoclonal antibodies (e.g., blinatumomab), denileukin
diftitox and
tumour-infiltrating lymphocytes (TILs).
[0104] Suitable targeted molecular therapies will be known to persons skilled
in the art.
Illustrative examples of suitable targeted molecular therapies include BRAF
inhibitors
(e.g., vemurafenib and dabrafenib), MEK inhibitors (e.g., trametinib and
cobimetinib), c-
KIT inhibitors (e.g., imatinib and nilotinib), tyrosine kinase inhibitors
(e.g., pazopanib and
axitinib) and mTOR inhibitors (e.g., everolimus).
[0105] A determinative factor for selecting a suitable therapeutic regimen for
the treatment
of melanoma is the stage of progression. For example, for a subject identified
as having a
more advanced stage of melanoma (as determined, e.g., by Stage assessment), a
more
aggressive therapeutic regimen may be prescribed as compared, for example, for
a subject
who has a less advanced melanoma (i.e., Stage 0, I or II), as determined, for
example, by
the methods disclosed herein.
[0106] As described elsewhere herein, therapeutic regimens will typically be
designed by a
medical practitioner or a team of medical practitioners, having regard, for
example, to the
age, weight, body mass index and general health of the subject, as noted
elsewhere herein.
[0107] In some embodiments, the therapeutic regimen comprises a combination of
two or
more treatment modalities (e.g., 2, 3 or more, 4 or more, 5 or more, 6 or
more). Treatment
modalities will typically be selected with a view to treating and/or
preventing melanoma
and/or melanoma recurrence.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
-32-
101081 As used herein the terms "treat", "treatment", "treating", "prevent",
"preventing"
and "prevention" refer to any and all uses which remedy a condition or
symptom, prevent
the establishment of a condition or disease, or otherwise prevent, hinder,
retard, abrogate
or reverse the onset or progression of a condition or disease or other
undesirable symptoms
in any way whatsoever. Thus, the terms "treating" and "preventing" and the
like are to be
considered in their broadest context. For example, treatment does not
necessarily imply
that a patient is treated until total recovery or cure. In conditions which
display or a
characterized by multiple symptoms, the treatment or prevention need not
necessarily
remedy, prevent, hinder, retard, or reverse all of said symptoms, but may
prevent, hinder,
retard, or reverse one or more of said symptoms. In the context of melanoma,
the agents,
uses, methods and protocols of the present disclosure that involve treatment
or prevention
may prevent, reduce, ameliorate or otherwise delay melanoma progression, or of
a highly
undesirable event associated with melanoma progression or an irreversible
outcome of
melanoma progression, but may not of itself prevent progression of the
melanoma or an
outcome associated therewith (e.g., a symptom associated with melanoma).
Accordingly,
treatment and/or prevention include amelioration of the symptoms of melanoma
progression or preventing or otherwise reducing the risk of melanoma
progression.
[0109] The term "inhibiting" and variations thereof, such as "inhibition" and
"inhibits", as
used herein, do not necessarily imply the complete inhibition of the specified
event,
activity or function. Rather, the inhibition may be to an extent, and/or for a
time, sufficient
to produce the desired effect. Inhibition may be prevention, retardation,
reduction,
abrogation or otherwise hindrance of an event, activity or function. Such
inhibition may
be in magnitude and/or be temporal in nature. In particular contexts, the
terms "inhibit"
and "prevent", and variations thereof may be used interchangeably.
Kits
[0110] In another aspect of the present disclosure there is provided a kit
comprising one or
more reagents and/or devices for use in performing the methods disclosed
herein. The kits
may contain reagents for analysing the expression of the one or more
autoantibodies
selected from the group consisting of anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-
PCTK1,
anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-TPM1 in
a
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 33 -
biological sample in accordance with the methods disclosed herein.
[0111] Kits for carrying out the methods of the present invention may also
include, in
suitable container means, (i) one or more reagents for detecting the one or
more
autoantibodies, (ii) one or more nucleic acid probes that specifically bind to
the nucleic
acid molecule(s) encoding each of the one or more autoantibodies, (iii) one or
more probes
that are capable of detecting and/or measuring the expression of the one or
more
autoantibodies, (iv) one or more labels for detecting the presence of the
probes and/or (iv)
instructions for how to measure the level of expression of the one or more
autoantibodies.
The container means of the kits will generally include at least one vial, test
tube, flask,
bottle, syringe and/or other container into which one or more reagents will be
placed or
suitably aliquoted. Where a second and/or third and/or additional component is
provided,
the kit will also generally contain a second, third and/or other additional
container into
which this component may be placed. Alternatively, a container may contain a
mixture of
more than one reagent, as required. The kits may also include means for
containing the one
or more reagents (e.g., nucleic acids) in close confinement for commercial
sale. Such
containers may include injection and/or blow-moulded plastic containers into
which the
desired vials are retained.
[0112] The kits may further comprise positive and negative controls, including
a reference
sample, as well as instructions for the use of kit components contained
therein, in
accordance with the methods disclosed herein.
[0113] All essential materials and reagents required for detecting and
quantifying the one
or more autoantibodies may be assembled together in a kit. The kits may also
optionally
include appropriate reagents for detection of labels, positive and negative
controls,
washing solutions, blotting membranes, microtiter plates, dilution buffers and
the like. For
example, a protein-based detection kit may include (i) one or more of the
autoantibodies in
the panel of autoantibodies selected from the group consisting of anti-ZBTB7B,
anti-
PRKCH, anti-TP53, anti-PC TK1, anti-PQB Pl, anti-UBE2V1, anti-IRF4, anti-
MAPK8 tv2, anti-MSN and anti-TPM1 (which may be used as a positive control),
(ii) one
or more antigens that are specific for the one or more of the autoantibodies
or probes that
specifically hybridize to one or more of the autoantibodies. Also included may
be
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 34 -
fluorescently conjugated monoclonal or polyclonal antibodies for the detection
of bound
autoantibodies. Such kits may also comprise, in suitable means, distinct
containers for
each individual reagent and enzyme as well as for each antibody or antigen.
The kit may
also feature various devices (e.g., one or more) and reagents (e.g., one or
more) for
performing any one of the assays described herein; and/or printed instructions
for using the
kit to quantify the expression of the one or more autoantibodies.
[0114] It will be appreciated that the above described terms and associated
definitions are
used for the purpose of explanation only and are not intended to be limiting.
[0115] In order that the invention may be readily understood and put into
practical effect,
particular preferred embodiments will now be described by way of the following
non-
limiting examples.
[0116] The reference in this specification to any prior publication (or
information derived
from it), or to any matter which is known, is not, and should not be taken as
an
acknowledgment or admission or any form of suggestion that that prior
publication (or
information derived from it) or known matter forms part of the common general
knowledge in the field of endeavour to which this specification relates.
[0117] All publications mentioned in this specification are herein
incorporated by
reference in their entirety.
[0118] The present disclosure is further described by reference to the
following non-
limiting examples.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 35 -
EXAMPLES
Materials and Methods
Study participants
[0119] A total of 245 study participants were recruited by collaborating
clinicians and the
principal researchers. All participants provided informed consent to
participate in this
study, previously approved by the Edith Cowan University Ethics Committee
(numbers
11543 and 12066). Patients were diagnosed by routine pathological examination
of their
excised primary tumour and staged according to the TNM staging system for
melanoma
according to the American Joint Committee on Cancer (AJCC) guidelines (Balch
et al.,
2009, Journal of Clinical Oncology, 27(36): 6199-6206). Healthy volunteers
were defined
as never having been diagnosed with cancer, melanoma or any autoimmune
disease. The
study cohort 1 included 104 early-stage melanoma patients (classified as TNM
stages in
situ, I and II) and 105 healthy volunteers. A smaller cohort consisting of 20
early stage
melanoma patients (classified as TNM stages in situ and I only) and 16 healthy
volunteers
(cohort 2) was used for validation purposes.
[0120] The participant characteristics are summarised below in Table 1. The
number of
males was higher than the number of females in both cohorts and in cohort 1,
patients were
significantly older than healthy volunteers (mean and standard deviation of
62.5 16.3
versus 56.5 12.9 years, p=0.003), however this was largely due to the
difference between
the male patients and healthy volunteers (63.7 versus 56.8 years, p=0.004).
There was no
significant difference in the mean age of female patients relative to controls
in cohort 1
(59.8 versus 55.7 years, p=0.309).
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 36 -
Table 1
Cohort 1 Cohort 2
Ntivattents*i*iNotunteersi*m
total cohort number 209 36
sample number 104 105 20 16
Female, n (%) 32 (30.8) 35 (33.3) 5 (25) 3
(18.8)
Male, n (%) 72 (69.2) 70 (66.7) 15 (75) 13
(81.2)
Mean age SD (years) 62.5 + 16.3 56.5 12.9 57.2 13.5 55.8
13.4
Age range (years) 20-96 20-83 26-76 25-80
= TNM stage, g.,(f4k,
0 (insitu) 45 (43.3) 15 (75)
38 (36.5) 5 (25)
II 21 (20.2). .. 0 (0)
Primary
(%)
Head and Neck 15 (14.4) 4 (20)
Trunk 43 (41.3) 9 (45)
Extremities 40 (38.5) 7 (35)
Multiple primary
melanoma with multiple 5 (4.8) 0 (0)
tumour sites
not reported 1 (1.0) 0 (0)
Melanonm.ubtyggi#041
ssm 13 (12.5) 3 (15)
NM 5(4.8) 0(0)
LMM 8(7.7) 0(0)
AIM 0(0) 0(0)
multiple CM subtypes 3 (2.9) 0 (0)
unclassified 25 (24) 9 (45)
not reported 50 (48.1) 8 (40)
UlcerationA(*
present 20 (19.2) 4 (20)
absent 57 (54.8) 14 (70)
not reported 27 (26) 2 .(.10).
Regression, &INI
present 36 (34.6) 7 (35)
absent 22 (21.2) 3 (15)
not reported 46 (44.2) 10 (50)
numbers are rounded to 1 decimal; SD, standard deviation; CM, cutaneous
melanoma;
SSM, superficial spreading melanoma; NM, nodular melanoma; LMM, lentigo
maligna
melanoma; ALM, acral lentiginous melanoma
Sample collection
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 37 -
[0121] A once-off blood sample was obtained from all study participants. For
melanoma
patients, the sample was obtained at the time, or within 3 months, of patient
primary
tumour diagnosis and excision. Venous blood from all study participants was
collected into
one 8.5 ml serum separator tube (SST) (BD, New Jersey, United States). The
blood was
allowed to clot at room temperature for a minimum of 30 mins and was
centrifuged at
1600 g for 10 mins. A small number of healthy volunteer samples (n=8) which
had been
collected into EDTA tubes were analysed from plasma. These samples were
included in
this study as serum and plasma samples have previously been found to yield
comparable
results in functional protein microarray studies (Gnjantic et al., supra).
Samples were
processed within 24 hours. Following centrifugation, serum was aliquoted and
stored at -
80 C until further use or until it was shipped to Sengenics, University of
Malaysia, Kuala
Lumpur, Malaysia, for the microarray screening of cohort 1 or to Oxford Gene
Technology
(OGT), Oxfordshire, United Kingdom, for the microarray screening of cohort 2.
Both
locations utilised the same microarray platform (OGT, UK) and Sengenics staff
received
training as well as ongoing advice from OGT directly. OGT and Sengenics staff
were
blinded to the fact that, for the purpose of cross-validation between the two
screening sites,
identical aliquots from 16 randomly selected patients and 11 healthy control
samples were
screened at both sites, and showed comparable results (rho > 0.5, Table 2)
enabling the use
of cohort 2 as an independent validation cohort.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 38 -
Table 2
Correlation Correlation
coefficient coefficient
Correlation
(rho) of twice (rho) of
coefficient
Sample ID (intra- and p-value once (intra- p-value
p-value
(rho) of raw
inter-array) array)
data
normalised normalised
data data
CM 17 0.769 <0.001
CM1 0.545 <0.001
CM10 0.849 <0.001
CM 12 0.076 0.372
CM 13 0.847 <0.001
CM 14 0.605 <0.001
CM15 0.803 <0.001
CM 19 0.750 <0.001
CM22 0.711 <0.001
CM24 0.851 <0.001
CM25 0.605 <0.001
CM3 0.586 <0.001
CMS 0.921 <0.001
CM6 0.808 <0.001
CM7 0.892 <0.001
CM8 0.712 <0.001
HC14 0.583 <0.001
HC17 0.579 <0.001
HC20 0.687 <0.001
HC22 0.699 <0.001
HC23 0.374 <0.001
HC25 0.628 <0.001
HC27 0.799 <0.001
HC28 0.678 <0.001
HC29 0.771 <0.001
HC30 0.220 0.009
HC32 0.487 <0.001
A total of 16 patient (CM) and 11 healthy control (HC) samples were run in
both study cohorts, rho and p-
values obtained through Spearman's Rho correlation, p<0.05 was considered
significant (bold)
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 39 -
Protein microarray profiling
[0122] The functional protein microarray was developed and constructed by
Oxford Gene
Technology (OGT), Oxfordshire, United Kingdom. Patient or control serum
samples were
diluted 1:200 in 2 ml buffer (0.1% Triton X100 (v/v), 0.1% BSA (w/v) in PBS)
and
applied to the array (one array per sample). The arrays were incubated in
Quadriperm
dishes (Greiner BioOne, Stonehouse, UK) and placed on a horizontal shaker at
50 rpm for
a period of 2 hours at room temperature. After several washes, anti-human IgG
was diluted
1:1000 in assay buffer and Cy3-rabbit anti-human IgG (Dako Cytomation) by
incubation
for 2 hours at room temperature according to the manufacturer's
recommendations. The
plate was washed again and dried by centrifugation. All arrays were scanned at
10 iLim
resolution using a microarray scanner (Axon 4200AL with GenePix Pro Software,
Molecular Devices, Sunnyvale, CA, USA) and fluorescence of labelled IgG was
detected
according to the manufacturer's instructions. Images were saved as 16-bit tiff
files and
analysis was performed using GenePix software. Interaction between microarray
antigens
and serum autoantibodies was detected as fluorescence of the bound
fluorescently-labelled
IgG at the protein specific position on the microarray. The intensity of
fluorescence is
proportional to the amount of autoantibody present in the serum. Local
background
obtained from control spots on the array was subtracted automatically and
relative
fluorescence units (rfu) for each microarray spot were recorded. Each antigen
was
immobilised in quadruplicate on the array. The median rfu for the four
readings of each
antigen was utilised for further analysis. A reference serum was included in
each
microarray experiment run. Arrays that did not pass quality control tests were
repeated or
the spots were realigned in the software or excluded. Thereafter, arrays were
excluded
from the analysis if they did not pass quality control.
Statistical analysis
Data normalisation
[0123] Intra- and inter-array data normalisation was performed to ensure data
comparability between samples. First, the overall median value of all median
rfu values of
the 1627 printed proteins (excluding data from controls spots) was calculated
and intra-
array normalisation was achieved by dividing the median of the quadruplicate
spots of
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 40 -
each protein on the array, by the overall median value of all the proteins on
the array in
each sample. Inter-array normalisation was achieved by utilisation of the
normalize.quantiles package in R (Bolstad et al., supra).
Selection of melanoma associated autoantibodies
[0124] Once normalised, a data analysis approach, as performed by Gnjatic et
al. (supra)
was utilised to determine the proteins with the highest and most frequent
seroreactivity in
patient samples relative to healthy volunteer sera. This was achieved by
calculating the
interquartile range (IQR) for each protein to establish a cutoff. This cutoff
(2.5xIQR above
the 75th percentile) was used to dichotomise the data, whereby a value was
defined as
positive (for seroreactivity) if it was above the cut-off; otherwise it was
defined as
negative. This criterion was used to ensure false positive data was minimised
while
providing increased specificity and sensitivity. For cases with positive
seroreactivity, the
ratio between the signal and cutoff (S/C ratio) was calculated. Thereafter,
the average S/C
ratio was calculated per biomarker for each cohort, i.e., melanoma patient or
healthy
control.
[0125] Finally, a "biomarker score" was assigned to each protein by
multiplying the
number of positive samples by the cubic root of the corresponding S/C ratio
average. This
score is a reflection of the strength and frequency of the signal in patients
relative to
healthy subjects. The proteins were then ranked based on the differences in
the biomarker
scores (patients ¨ healthy controls). A large AAb biomarker score (>5)
indicates that most
seroreactivity is attributable to the patients. This reduced the number of
potential
diagnostic melanoma autoantibody biomarkers from 1627 to 139 in cohort 1
(Table 3).
Selection of biomarker panel
[0126] Combinations of identified biomarkers, rather than individual
biomarkers for early
melanoma detection, were assessed to achieve greater sensitivity and
specificity. The
classification tree method was selected for this task and this analysis was
performed using
data from cohort 1 only as cohort 2 was not sufficiently powered. The number
of variables
(i.e., 139 antigens) at this stage was still reasonably large relative to the
overall sample
size. To avoid the possibility of overfitting, a two-stage process was
utilised, as follows:
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 41 -
[0127] Stage 1 involved the use of random forest regression analysis (Brieman,
2001) for
identifying key biomarker proteins and to further reduce the number of
biomarkers in
contention for the next modelling stage. Stage 2 utilised the classical
classification tree
approach (Brieman, 1984) to develop a tree model based on the reduced list of
biomarkers.
[0128] All analyses were implemented with the R software package (Version
3.2.2; R
Core Team, 2013). The key R packages used were randomForest (Liaw & Wiener,
2002,
R News, 2: 18-22), rpart (Therneau et al., 2015) and caret (Kuhn, 2015).
Additional statistical analysis
[0129] To test whether the data was approximately normally distributed, a
Shapiro-Wilk' s
test (p>0.05; Shapiro & Wilk, 1965, Biometrica, 52(3/4): 591-611), visual
inspection of
histograms, normal Q-Q plots and box-plots were performed. The majority of the
data in
this study was not normally distributed. To assess whether AAb serum scores
and other
continuous measures varied between levels between two independent groups of
samples
(i.e., patients and healthy controls), a Mann-Whitney U test or the parametric
equivalent
independent t-test was used. For this analysis, a "serum score" was calculated
from the
twice normalised data for each sample by determining the sum of all signal
intensities
above the antigen-associated cut off for each protein of interest (Zayakin et
al., supra). For
comparison of categorical covariates between groups such as TNM stage, gender,
tumour
location and others, Chi-square or Fisher's exact tests were utilised. To
assess whether
various patient demographics or features of their primary tumour were
accountable for
changes in the patient serum scores of the identified top 139 biomarkers as
well as the
frequency of positive AAb responses in each patient, Bivariate Spearman's Rho
correlation
analysis was performed. Sensitivity and specificity of individual and
combinations of
AAbs were evaluated by ROC. These analyses were performed using Microsoft
Excel,
SPSS statistical software (version 22.0) and GraphPad Prism (version 5). A p-
value of
<0.05 was defined as statistically significant.
[0130] Finally, to explore the biological relevance of the identified
autoantibody
biomarkers and their interactions, we submitted the top 139 antigen names to
STRING the
online functional protein association network in order to explore the main
shared antigen
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 42 -
pathways at medium protein interaction confidence of 0.400. The submitted
protein names
are identical to Table 3 while protein PCTK1 and SDCCAD10 were searched by
their
alternative names CDK16 and CWC27, respectively.
Results
(A) The expression of one or more autoantibodies correlates with early stage
melanoma
[0131] In cohort 1, a total of 748 antigens reacted preferentially with the
patient sera as
indicated by their positive biomarker scores. Of those, 139 resulted in scores
of 5 or greater
and were therefore considered to have a potential diagnostic value (Table 3).
The majority
of the identified 139 antigens displayed very high specificity ranging from
86.7% - 100%
(mean of 97%), while their sensitivity as single biomarker ranged from 2.9% to
18.3%
(mean of 9.9%). Notably, 20/139 (14.4%) antigens did not react with any of the
healthy
control samples. Most of the identified markers are novel and are not known
for their
association with melanoma. It is, however, important to note that many were
reactive
against, transcription factors that may influence an array of cancer-related
pathways,
tumour suppressors and promoters, markers of apoptosis, and regulators of
pigmentation
and T-cell differentiation. Some of the top 139 seroreactive antigens such as
VEGFb, p53,
KIT and MLANA have previously been associated with melanoma or cancer in
general,
thus supporting that the detected autoantibody response is derived from an
anti-tumour
response.
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
-43 -
Table 3
average average
difference
signal signal to overall in
cohort
overall
Sensitivity Specificity to cutoff score
scores
Protein cutoff score
(%) (%) cutoff ratio for .
healthy (patients -
ratio for healthy patientsvolunteers
healthy
patients volunteers
volunteers)
PRKCH 18.3
95.2 1.21 3.73 1.44 29.47 5.65 23.82
PCTK3 16.3
96.2 1.25 7.42 20.62 33.16 10.97 22.19
DPF2 15.4
96.2 1.47 5.59 4.75 28.40 6.72 21.68
KIT 17.3
95.2 1.06 2.50 2.36 24.42 6.65 17.77
KLK3 16.3
95.2 1.25 2.53 2.24 23.16 6.54 16.62
STK38L 15.4
95.2 1.60 3.21 2.85 23.60 7.09 16.50
STMN1 16.3
92.4 2.65 3.38 1.47 25.51 9.11 16.41
DLX3 16.3
98.1 0.96 1.11 1.14 17.60 2.09 15.51
ZBTB7B 16.3
98.1 0.92 1.13 1.49 17.71 2.29 15.43
ASB1 16.3
95.2 1.17 2.00 1.76 21.43 6.04 15.40
CASP7 14.4
95.2 1.64 4.27 6.22 24.33 9.19 15.14
RAC2 16.3
96.2 1.10 1.56 1.78 19.70 4.85 14.85
HBG1 13.5
98.1 1.14 1.73 1.16 16.81 2.10 14.71
NFE2L2 15.4
98.1 1.14 1.11 1.09 16.56 2.06 14.50
ELK1 12.5
97.1 3.52 2.64 1.65 17.97 3.54 14.43
EZH2 15.4
98.1 1.03 1.09 1.33 16.47 2.20 14.27
PDGFRL 18.3
93.3 1.07 1.64 1.58 22.42 8.15 14.27
HRH2 16.3
93.3 1.20 2.54 2.14 23.19 9.02 14.17
TP53 10.6
98.1 5.79 3.15 1.19 16.12 2.12 14.01
EXT2 17.3
95.2 1.09 1.20 1.16 19.12 5.25 13.87
PYGO2 13.5
94.3 1.90 3.29 1.83 20.83 7.34 13.48
SERPINB5 14.4 98.1 1.02 1.14 1.32 15.68 2.20 13.48
NR1I2 13.5
99 0.99 1.11 1.11 14.49 1.04 13.46
XYLB 16.3
95.2 1.48 1.32 1.24 18.67 5.37 13.31
PHIP 16.3
95.2 1.22 1.31 1.30 18.59 5.46 13.13
CCNB1 10.6
96.2 3.10 4.43 2.17 18.07 5.18 12.89
STAT5A 13.5
97.1 1.05 1.44 1.09 15.81 3.09 12.72
RAD23B 15.4
94.3 3.16 1.92 1.82 19.88 7.33 12.55
IF116 13.5
98.1 1.03 1.14 1.27 14.62 2.16 12.45
TUBB 10.6
97.1 1.18 3.40 2.78 16.54 4.22 12.33
SMARCE1 16.3 94.3 0.80 1.34 1.28 18.73 6.52 12.21
MSN 9.6
98.1 2.42 2.92 1.90 14.29 2.48 11.81
ZNF169 10.6
98.1 1.31 2.34 2.77 14.60 2.81 11.79
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 44 -
HSPA1A 10.6
97.1 1.48 2.55 1.28 15.04 3.26 11.78
DR1 14.4
91.4 1.71 3.07 1.40 21.80 10.07 11.73
SLC25A6 14.4
95.2 1.09 1.42 1.48 16.86 5.69 11.17
TRAF2 9.6 98.1
4.39 2.13 1.18 12.87 2.11 10.76
BAD 16.3
94.3 1.45 2.82 11.15 24.03 13.41 10.62
PKNOX1 9.6 98.1
6.32 2.15 2.00 12.91 2.52 10.39
PCTK1 11.5
97.1 6.05 1.65 2.35 14.19 3.99 10.20
FOXR2 17.3
91.4 5.94 1.98 2.70 22.60 12.53 10.06
EZR 7.7 98.1
2.09 3.39 1.22 12.02 2.14 9.88
PPP2CB 12.5
96.2 1.45 1.33 1.41 14.31 4.49 9.82
UBE2V1 4.8 99 1.70
9.97 1.27 10.76 1.08 9.68
JUNB 10.6
98.1 1.18 1.20 1.16 11.69 2.10 9.60
BIRC7 12.5
95.2 3.46 1.63 1.59 15.31 5.83 9.48
STK10 9.6 98.1
1.81 1.53 1.31 11.53 2.19 9.35
DSTYK 13.5
95.2 1.18 1.10 1.12 14.45 5.19 9.26
MTERF 10.6
98.1 0.99 1.13 1.86 11.46 2.46 9.00
FEN1 8.7 92.4
4.47 8.88 1.86 18.64 9.85 8.79
KLF12 7.7 100
1.24 1.28 0.00 8.68 0.00 8.68
MEF2A 9.6 96.2
2.23 2.97 3.01 14.37 5.77 8.60
SCFD1 8.7 97.1
1.49 2.37 1.46 12.00 3.40 8.60
ZNF444 8.7 99 1.08
1.21 1.06 9.60 1.02 8.58
STAP1 13.5
92.4 3.61 2.29 1.93 18.45 9.96 8.49
CDK2 9.6 96.2
3.94 2.41 1.86 13.41 4.92 8.49
NFYA 8.7 98.1
1.30 1.62 1.15 10.56 2.10 8.47
TGIF1 8.7 99 1.26
1.12 1.09 9.36 1.03 8.33
RPL32 10.6
97.1 1.28 1.11 1.10 11.38 3.10 8.29
DLX1 7.7 100
1.09 1.10 0.00 8.26 0.00 8.26
XBP1 9.6 98.1
1.07 1.17 1.57 10.54 2.32 8.22
IMPA1 8.7 99 1.51
1.08 1.08 9.22 1.03 8.20
PLD2 9.6 98.1
1.06 1.07 1.17 10.23 2.11 8.12
ACVR2A 15.4
90.5 2.23 2.18 2.03 20.75 12.66 8.09
PQBP1 9.6 97.1
2.99 1.40 1.42 11.18 3.37 7.81
TTF2 5.8 100
1.27 2.16 0.00 7.76 0.00 7.76
USH1C 7.7 98.1
4.74 1.90 1.42 9.91 2.25 7.67
HEXIM1 7.7 97.1
1.82 2.43 1.11 10.76 3.10 7.66
LRRFIP2 10.6
95.2 4.45 2.15 2.32 14.19 6.62 7.58
CEPSS 7.7 99 2.29
1.21 1.01 8.52 1.00 7.52
SCAND1 5.8 97.1
1.42 5.65 1.21 10.69 3.20 7.49
VEGFB 7.7 97.1
3.24 2.75 2.03 11.21 3.80 7.41
HEYL 6.7 100
1.20 1.18 0.00 7.41 0.00 7.41
RQCD1 6.7 99 2.71
1.81 1.53 8.53 1.15 7.38
SDCCAG10 11.5 93.3 3.08 2.16 1.56 15.50 8.12 7.38
MLANA 5.8 98.1
2.59 4.27 1.77 9.73 2.42 7.32
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 45 -
HNF1B 6.7 100
1.16 1.14 0.00 7.31 0.00 7.31
MAPK8_tv2 5.8 99 2.60
2.72 1.26 8.37 1.08 7.30
PSME2 6.7 98.1
2.01 2.42 1.21 9.40 2.13 7.27
NDRG2 7.7 98.1
2.12 1.63 1.24 9.41 2.15 7.26
FOXA3 6.7 100
1.31 1.11 0.00 7.26 0.00 7.26
CKB 3.8 100
3.68 5.94 0.00 7.24 0.00 7.25
ZNF449 7.7 99 1.17
1.07 1.02 8.19 1.01 7.18
PBX1 8.7 98.1
1.06 1.07 1.05 9.21 2.03 7.18
TPM1 8.7 97.1
9.02 1.86 2.19 11.06 3.90 7.17
NME5 8.7 97.1
1.63 2.17 3.87 11.65 4.71 6.94
GTF2A2 8.7 98.1
1.08 1.05 1.45 9.16 2.26 6.90
CCND1 4.8 100
1.66 2.53 0.00 6.81 0.00 6.81
PAPSS2 7.7 98.1
5.97 1.67 2.59 9.49 2.75 6.75
STAT4 7.7 98.1
2.59 1.57 2.25 9.31 2.62 6.68
CBFA2T3 15.4
89.5 4.14 2.80 3.01 22.54 15.89 6.66
HMGB2 8.7 94.3
1.89 2.93 1.19 12.88 6.35 6.53
CCDC33 8.7 97.1
2.57 1.85 3.46 11.04 4.54 6.51
AK2 6.7 98.1
2.29 2.16 2.25 9.04 2.62 6.42
SMAD2 7.7 98.1
3.61 1.44 2.23 9.03 2.61 6.42
FMR1NB 6.7 99 1.53
1.13 1.04 7.30 1.01 6.29
FAF1 9.6 95.2
2.89 2.30 2.68 13.21 6.95 6.26
CREB5 6.7 99 1.29
1.11 1.03 7.24 1.01 6.23
ZFP36L1 6.7 99 1.20
1.11 1.05 7.24 1.01 6.22
IRF4 5.8 100
2.59 1.11 0.00 6.22 0.00 6.22
PTPN20A 14.4 89.5 3.87 2.46 2.08 20.26 14.04 6.21
C1orf216 5.8 98.1
2.58 2.57 1.02 8.22 2.01 6.21
HSFY1 5.8 100
1.07 1.09 0.00 6.17 0.00 6.17
KIF9 4.8 98.1
1.13 4.89 1.57 8.49 2.32 6.17
RING1 5.8 99 1.32
1.70 1.03 7.17 1.01 6.15
PRDM4 6.7 99 1.13
1.22 2.31 7.48 1.32 6.15
MAFG 7.7 98.1
1.16 1.14 1.35 8.36 2.21 6.15
MECP2 7.7 98.1
1.09 1.11 1.24 8.29 2.15 6.14
HOXB6 7.7 98.1
1.09 1.14 1.41 8.36 2.24 6.11
MUTYH 6.7 99 1.09
1.08 1.59 7.17 1.17 6.01
CDC25A 4.8 100
1.72 1.64 0.00 5.90 0.00 5.90
CDKN2C 5.8 99 1.88
1.53 1.23 6.92 1.07 5.85
SUPT4H1 2.9 100
1.83 6.94 0.00 5.72 0.00 5.72
CHEK2 5.8 99 1.71
1.49 1.87 6.85 1.23 5.62
BIRC5 5.8 99 2.18
1.35 1.30 6.64 1.09 5.55
INPP1 6.7 98.1
1.53 2.92 11.15 10.01 4.47 5.54
TXN2 12.5
91.4 3.37 2.16 1.97 16.81 11.28 5.53
CBLC 4.8 99 3.14
2.51 2.04 6.79 1.27 5.52
ANXA11 8.7 94.3
1.76 2.58 1.51 12.35 6.89 5.46
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 46 -
MAX 8.7 93.3
2.59 3.71 1.78 13.94 8.48 5.46
SLCO6A1 7.7 97.1
1.59 1.29 1.38 8.71 3.34 5.37
EEF1D 6.7 98.1
4.94 1.23 1.23 7.49 2.14 5.35
TLX2 4.8 100
1.16 1.20 0.00 5.31 0.00 5.31
HORMAD1 4.8 100 1.28 1.19 0.00 5.30 0.00 5.30
CTNNA2 7.7 94.3
2.50 3.55 1.54 12.20 6.92 5.28
GTF2H1 7.7 97.1
0.97 1.26 1.41 8.65 3.37 5.28
HCFC2 9.6 95.2
1.05 1.11 1.08 10.36 5.12 5.24
TBX6 4.8 100
1.09 1.13 0.00 5.21 0.00 5.21
PATZ1 5.8 99 1.08
1.09 1.02 6.18 1.01 5.17
BTG3 4.8 100
1.01 1.10 0.00 5.17 0.00 5.17
PDPK1 14.4
86.7 3.29 4.43 2.69 24.63 19.47 5.16
WAS 4.8 100
1.38 1.09 0.00 5.14 0.00 5.14
TBK1 4.8 100
1.30 1.08 0.00 5.13 0.00 5.13
TBX5 4.8 100
1.03 1.08 0.00 5.12 0.00 5.12
NLK 12.5
92.4 2.36 1.42 1.67 14.61 9.50 5.11
MEOX2 4.8 100
1.16 1.06 0.00 5.10 0.00 5.10
STUB1 8.7 94.3
3.63 2.70 1.91 12.53 7.44 5.08
BAG3 6.7 98.1
7.03 1.26 1.97 7.56 2.51 5.05
GMEB1 10.6
92.4 1.66 2.71 2.14 15.34 10.31 5.03
[0132] As mentioned in the materials and methods section, "serum scores" were
calculated
for each sample using the twice normalised data by calculating the sum of all
signal
intensities above the antigen-associated cut off for each of the top 139
antigens to compare
the overall seroreactivity levels between the patient and control cohort. For
melanoma
patients, the median serum score was 60.5 (IQR 33.9 - 95.9) and 15.5 (IQR 6.7 -
27.7) for
healthy controls, a highly statistically significant difference (p<0.0001,
Figure 2A).
[0133] To evaluate the diagnostic performance of the identified biomarkers in
a different
cohort of samples, we calculated the serum scores for the top 139 biomarkers
using the 36
samples included in cohort 2. Patient serum scores were again significantly
higher, with a
median of 51.1 (IQR 38.7 - 77.7) compared to healthy control median serum
score of 38.9
(IQR 14.1 - 53.7, p=0.029, Figure 2B), supporting the validity of the top 139
biomarkers.
[0134] The breadth of AAb responses against the protein microarray of 1627
proteins
varied between samples. Positive autoantibody production in a sample was
defined as a
fluorescence reading above the protein associated cut off. Positive
autoantibody production
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 47 -
to at least one of the proteins was observed in every study participant sample
in cohort 1.
Out of the 1627 antigens on the array, patient sera reacted with a median of
46.0 (IQR 36.0
¨ 70.0) antigens while healthy control sera reacted with a median of 48.0 (IQR
40.5 ¨ 57.0)
antigens (p=0.857). 100% of patient samples and 92.4% of healthy control
samples reacted
with at least one of the top 139 antigens. In total, a sum of 1426 positive
antibody
responses against the top 139 antigens were observed in the 104 patients while
only 434
positive antibody responses were observed in the 105 healthy controls. A
statistically
significant difference was observed between the number of individual patient
and healthy
control sample AAb responses against the 139 antigens (median of 9.0 (IQR 6.0
¨ 22.0)
versus 3.0 (IQR 1.0 ¨ 4.0), respectively, p<0.001). The median number of AAb
responses
was also significantly different between patient and healthy control samples
for the
identified AAb biomarker combination of 10 autoantibodies, with patient
samples
displaying a median of 1.0 (IQR 1.0 ¨ 1.0, range 0 ¨ 3.0) when compared the
control
median of 0 (IQR 0 ¨ 0, range 0¨ 2.0), p<0.001.
[0135] None of the patient characteristics or features of the corresponding
primary tumour
correlated with the serum score or frequency of positive AAb reactions against
the top 139
antigens (Table 5). We observed a strong correlation between the tumour
mitotic rate and
Breslow thickness (r=0.500, p<0.001) as well as between TNM stage and Breslow
thickness (r=0.903, p<0.001). Serum scores and frequency of positive AAb
responses also
displayed a strong correlation (r=0.776, p<0.001) as expected since the serum
score is
calculated based on the positive AAb serum reactions. Other weak and moderate
correlations were observed, including a moderate correlation between patient
age and
whether a patient was diagnosed with multiple melanoma throughout their life
(r=0.362,
p<0.001). Since the risk of further melanoma development increases with age,
it is not
surprising that these measures correlate. Interestingly, we observed a
moderate negative
correlation between the presence of multiple melanomas and the presence of
tumour
regression (r=-0.304, p=0.002).
CA 03063904 2019-11-18
WO 2018/213877
PCT/AU2018/050492
- 48 -
Table 5
...k .1 __________
.:
. .1 ,
f
A
A .
Irt "
4 ............................................. a , n1 ',4. ............. a
,.?; A g...24 4
$f g
4
a I 4. .............................................................. I ,1 .4
II Ai A ii I
,k., ...:
.... k K 13 "t It ................ t:......:4õ 1 .. h 4. 7
.. . , ...
4i
s
.1.õ 5õõõNõõ.",õ nõõA:õõ,:aõ,..4: gi õ..1õ, 4 .........................
t
, .. fi :4: =K :sti_zii __ 1 4 _______ ,!: _____________________ .21¨A.
..4.... t .g 4 fi_ 4 V.:-. ; :4 LL
A*
$ _______________________________________ 1,s 1s4 R:õõ,i_ s A ..z=
....4A_Lõ,' 4 A::õõ1 1
4
..
2:
,
1 ..,..z I = 't
IN: -,=,: 1 A A 4.,,,
i .=..i I t
,.:..
1
1
1
:t .4
P
I D
4.
1:
4 :4
:
x. t
A
iz
..k,'
...x.,
,S
A
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 49 -
(B) Melanoma-associated autoantibodies are functionally correlated with cancer
pathways associated with melanomagenesis
[0136] A STRING protein association network of the top 139 antigens was
generated
(Figure 3). Interestingly, the majority of the seroreactive proteins are
antigens intracellular
proteins (101/139) of which the majority are contained within the nucleus
(88/139), a
cellular location that is usually protected from immune surveillance cells.
Many cancer
autoantibody studies have however also reported detection of AAbs against
nuclear
antigens in other cancers and this has been suggested to be due to spillage of
the
intracellular contents into the surrounding tissue following cell death in
cancer (Zaenker et
al., supra). Furthermore, the top 139 identified biomarkers appear related to
primarily to
general cancer pathways, apoptosis, pathways associated with the immune
response and
cell cycle, p53 signalling and the MAPK signalling pathway, the main pathway
associated
with melanomagenesis, highlighting the biological relevance of the identified
biomarkers.
(C) The expression of a combination of the anti-ZBTB7B, anti-PRKCH, anti-TP53,
anti-
PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2, anti-MSN and anti-
TPM1 autoantibodies correlates with early stage melanoma
[0137] Since the development of a diagnostic blood test that is comprised of
139
biomarkers is impractical and hence not clinically applicable, we utilised a
two stage
analysis approach involving random forest and classification tree analysis to
identify a
combination of 10 biomarkers or less with the highest diagnostic potential.
[0138] Following random forest analysis of the data from cohort 1, the top 20
most
influential markers for a diagnostic model were identified with the most
important AAbs
were given a rank score of 20 and the least important marker given a score of
1. This
analysis was repeated 1000 times to generate 1000 random forests. When the top
20
markers of each of these 1000 forests were combined, a list of 27 unique
biomarkers and
their percent model inclusion frequency (Figure 4A), with potential to aid in
melanoma
diagnosis, were identified. The number and proportion of the appearance of
each of these
biomarkers in the 1000 top 20 AAb lists was then multiplied by the average
rank score to
obtain a weighted mean rank by which the overall importance of the biomarker
for
CA 03063904 2019-11-18
WO 2018/213877 PCT/AU2018/050492
- 50 -
melanoma diagnosis was determined. A sorted list of the most important
biomarkers and
their corresponding weighted mean rank scores are shown in Figure 4B. In
cohort 1,
patient serum scores for these 27 antigens were again significantly higher
with a median of
10.2 (IQR 4.7 ¨ 19.1), than the healthy control median serum score of 0 (IQR 0
¨ 1.6,
p<0.0001, Figure 5A) while, possibly due to the low sample size, there was no
significant
difference between patient and controls serum scores in cohort 2 (median of
11.2 (IQR 6.2
¨ 22.0) versus 5.5 (1.4 ¨ 16.9), p=0.176, Figure 5B). Interferon regulator 4
(IRF4) was the
most frequently included biomarker in the 1000 combinations that displayed the
highest
average rank score and was therefore the most important marker to contribute
to the
overall sensitivity and specificity in a combination of AAbs. As a single
biomarker, IRF4
displayed a sensitivity of 5.8% at 100% specificity.
[0139] Classification tree analysis was then applied to these 27 biomarkers
and showed
that the best combination of biomarkers ensuring an increased sensitivity and
specificity
for melanoma diagnosis, is a signature of 10 AAbs, including anti-ZBTB7B, anti-
PRKCH,
anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8 tv2,
anti-
MSN and anti-TPM1 (Figure 6), with a combined sensitivity of 79%, specificity
of 84%
and an AUC of 0.828 (Figure 7 and 8). The biomarkers included in the panel did
not
necessarily display the highest individual diagnostic potential (Table 3).
Instead, they are a
combination, displaying a broader occurrence of positive seroreactivity for
patient sera if a
positive diagnosis is said to be represented by positive seroreactivity with
at least one or
more of the biomarkers in the combination.
[0140] Unlike other autoantibodies that have been suggested to be suitable
prognostic
biomarkers for melanoma, this is the first study to investigate the presence
of AAbs in
early stage melanoma. Furthermore, no previous studies have utilised a
screening approach
using the individual patient autoimmune repertoire against an unbiased array
of proteins.
Therefore, the inventors have been the first to identify AAbs as diagnostic
biomarkers in a
large cohort of primary melanoma patients compared to healthy volunteers using
a high-
throughput functional microarray platform.
